KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
के लिए फिर से शुरू Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi: आँकड़ों को प्रभावित करें
रिपोर्ट चलाएं
| Concept | World rank |
|---|---|
| cipnmethodspatients | #1 |
| motor subscales | #1 |
| postsurgical neuropathic pain | #1 |
| pilot trial hands | #1 |
| baseline prognosis | #1 |
| patientcompleted questionnaires | #1 |
| mascc isoo evidence | #1 |
| tingling numbness | #1 |
| hot flashes day | #1 |
| antiemetic prescribing practices | #1 |
| bortezomib alters | #1 |
| guidelineendorsed treatment | #1 |
| 65 day | #1 |
| effects hot flashes | #1 |
| venous toxicity fosaprepitant | #1 |
| glutamine toxicity | #1 |
| a151408 study data | #1 |
| joints syndrome | #1 |
| metastatic disease initiation | #1 |
| association arhgef10 | #1 |
| suggestion pregabalin | #1 |
| prevention cipn | #1 |
| safety oestrogen | #1 |
| incurable cancer records | #1 |
| women megestrol acetate | #1 |
| diphenhydraminelidocaineantacid | #1 |
| cipn data | #1 |
| chemotherapy response rates | #1 |
| taxane infusion | #1 |
| flash therapies | #1 |
| tested interventions lymphedema | #1 |
| grade peripheral neuropathy | #1 |
| isae data | #1 |
| oxybutynin doses | #1 |
| symptoms hormone deprivation | #1 |
| extreme phenotyping | #1 |
| alliance trial | #1 |
| anorexia appetite | #1 |
| prevention paps | #1 |
| acetate dexamethasone | #1 |
| cipn postural control | #1 |
| neuronal uptake transporters | #1 |
| ncctg trial n06ca | #1 |
| treatment hot flashes | #1 |
| paps fatigue | #1 |
| ncctg n08c3 | #1 |
| 43 oral complications | #1 |
| ambulatory patients opioids | #1 |
| nonestrogenic management | #1 |
| cancer anorexia cachexia | #1 |
| or1 year patients | #1 |
| nasal vestibulitis | #1 |
| uncertain gbu gbu | #1 |
| effects cipn | #1 |
| purposehot flashes | #1 |
| creatine placebo groups | #1 |
| n08cb alliance | #1 |
| cipn20 questionnaire | #1 |
| hot flash scores | #1 |
| n08c3 | #1 |
| ru221408i | #1 |
| tpn initiation death | #1 |
| vitamin cipn | #1 |
| aimss life | #1 |
| therapy numbness | #1 |
| induced neurotoxicity oct2 | #1 |
| lymphedema prevention education | #1 |
| hfs symptoms patients | #1 |
| fractures infertility | #1 |
| placebo 15 glutathione | #1 |
| management hot | #1 |
| newer antidepressants gabapentin | #1 |
| tingling | #1 |
| lignans 6 weeks | #1 |
| reduction hot | #1 |
| prevention induced cipn | #1 |
| oncologists prognostic | #1 |
| weeks hot | #1 |
| patients hot flashes | #1 |
| sensory subscale | #1 |
| numeracy adjuvant | #1 |
| symptoms hands | #1 |
| single snv rs9657362 | #1 |
| 1year survival trials | #1 |
| nonfluid | #1 |
| leucovorin breast cancer | #1 |
| phytotherapy vitamin | #1 |
| enoxaparin cvte | #1 |
| stellate ganglion block | #1 |
| agents humans clinicians | #1 |
| historical placebo response | #1 |
| acetate appetite | #1 |
| aps paclitaxel | #1 |
| treatment attribution | #1 |
| − fsfi | #1 |
| accru study | #1 |
| hot flashes quality | #1 |
| hours nighttime sleep | #1 |
| aminobutyric acid adt | #1 |
| oxybutynin hot flashes | #1 |
| differences neuropathy syndromes | #1 |
| pilot evaluation | #1 |
| slight appetite stimulation | #1 |
| anecdotal observations gabapentin | #1 |
| recommendation prevention | #1 |
| day cisplatin therapy | #1 |
| toxicity agent | #1 |
| head therapeutic equivalency | #1 |
| antidepressants gabapentin | #1 |
| cyclohexanols female | #1 |
| nonhormonal agents | #1 |
| lidocaine antacid | #1 |
| relatedness treatment | #1 |
| eortc qlqcipn20 instrument | #1 |
| cinv day | #1 |
| patients dosing guidelines | #1 |
| placebo oral mucositis | #1 |
| backgrounddehydroepiandrosterone | #1 |
| rs9657362 | #1 |
| n08ca patients | #1 |
| conducted studies hrt | #1 |
| isae | #1 |
| diseases pilot | #1 |
| hormone deprivation cancer | #1 |
| leap 12 months | #1 |
| antiemetic prescribing | #1 |
| response relationship odc | #1 |
| institutional guidelines patients | #1 |
| middle aged minocycline | #1 |
| 5fuinduced stomatitis | #1 |
| tpn death | #1 |
| digital melt curve | #1 |
| hot flashes weeks | #1 |
| antacid mouthwash | #1 |
| drowsiness doxepin mouthwash | #1 |
| mouthwash diphenhydramine | #1 |
| gabapentin hot | #1 |
| hot flashes treatment | #1 |
| cancers prevalence | #1 |
| antibiotic lozenge placebo | #1 |
| placebos pregabalin quality | #1 |
| neuropathy data | #1 |
| treatment hot | #1 |
| cancerassociated anorexia cachexia | #1 |
| complete response authors | #1 |
| inadequate control antidepressant | #1 |
| managing hot | #1 |
| routine feces sensitivity | #1 |
| bothersome hot | #1 |
| glutathione cipn | #1 |
| painful oxaliplatininduced cipn | #1 |
| doxepin mouthwash placebo | #1 |
| skin dermatitis trials | #1 |
| weight megestrol acetate | #1 |
| weight loss investigation | #1 |
| daily hot | #1 |
| cipn20 sensory | #1 |
| benefit fluoxetine | #1 |
| 20 data patients | #1 |
| individuals cipn | #1 |
| n08ca | #1 |
| baseline assessment week | #1 |
| udi scores baseline | #1 |
| ulabtka placebo cream | #1 |
| active nonhormonal | #1 |
| baseline prognosis values | #1 |
| supportive cytotoxic chemotherapy | #1 |
| methylphenidate cancer patients | #1 |
| items uncertain gbu | #1 |
| gabapentin arm | #1 |
| adjuvant numeracy | #1 |
| improvements hot flashes | #1 |
| neuropathy 20 | #1 |
| women inadequate control | #1 |
| cryotherapy hands | #1 |
| n08c1 | #1 |
| treating institution intervention | #1 |
| compounded topical gel | #1 |
| ocular ice packs | #1 |
| management genital symptoms | #1 |
| benefit 5fu | #1 |
| megestrol acetate nausea | #1 |
| bothersome hot flashes | #1 |
| life study arms | #1 |
| pilot study minocycline | #1 |
| ganglion surveys | #1 |
| acetate versus | #1 |
| acetate doses | #1 |
| cipn methods | #1 |
| inadequate hot | #1 |
| baseline neuropathic pain | #1 |
| acceptability ssc device | #1 |
| items positive indication | #1 |
| flashes patients | #1 |
| ulabtka | #1 |
| life megestrol acetate | #1 |
| cipn phase iii | #1 |
| sham acupuncture participants | #1 |
| resected cutaneous melanomas | #1 |
| cytotoxic chemotherapy supportive | #1 |
| nonfluid weight | #1 |
| patientreported outcomes balance | #1 |
| subcutaneous testosterone improvements | #1 |
| neoplasm recurrence apixaban | #1 |
| flash score | #1 |
| prevent oxaliplatin | #1 |
| lenolidamide | #1 |
| recommended colorectal | #1 |
| n06ca | #1 |
| magnesium camg | #1 |
| education lymphedema prevention | #1 |
| cipn common | #1 |
| shooting burning | #1 |
| nsclc response rate | #1 |
| neuropathy randomized | #1 |
| hot flashes | #1 |
| flaxseed bar lignans | #1 |
| arhgef10 cipn | #1 |
| small cell continuity | #1 |
| patients paclitaxel polyneuropathy | #1 |
| developed mucositis | #1 |
| toxicity prospective trial | #1 |
| fluoxetine hot | #1 |
| hot flash activity | #1 |
| fluorouracilinduced stomatitis | #1 |
| toxicity anecdotal observations | #1 |
| numbness tingling | #1 |
| cachexia studies | #1 |
| oral cryotherapy | #1 |
| individual patients understanding | #1 |
| paclitaxel favor | #1 |
| preliminary evidence improvement | #1 |
| estimated benefit dfs | #1 |
| agents antihypertensive agents | #1 |
| oil nasal | #1 |
| qlq cipn20 | #1 |
| residual hot flashes | #1 |
| anorexia antineoplastic agents | #1 |
| points doxepin | #1 |
| women 65 day | #1 |
| deprivation therapy patients | #1 |
| survivors genitourinary syndrome | #1 |
| 2007 guidelines suggestion | #1 |
| antibiotic lozenge | #1 |
| infliximab lung | #1 |
| appetite stimulation patients | #1 |
| individuals impaired balance | #1 |
| therapeutic targets cipn | #1 |
| anecdotal observations | #1 |
| rose geranium | #1 |
| aes relatedness | #1 |
| paclitaxel polyneuropathy | #1 |
| hormone deprivation | #1 |
| cipn nervous diseases | #1 |
| premenopause radiotherapy | #1 |
| cipn paps | #1 |
| balance patientreported outcomes | #1 |
| flashes breast | #1 |
| flashes prospective | #1 |
| cipn function | #1 |
| extensive animal data | #1 |
| hot flashes gabapentin | #1 |
| rs9657362 previous study | #1 |
| dmc assay | #1 |
| oral mucositisrelated pain | #1 |
| cvte rivaroxaban | #1 |
| placebo pilot trials | #1 |
| oncology providers crci | #1 |
| tpn female services | #1 |
| coasting phenomenon | #1 |
| nonhormonal therapies paroxetine | #1 |
| hot flash mechanism | #1 |
| patients nasal vestibulitis | #1 |
| fosaprepitant isae | #1 |
| overview oncology providers | #1 |
| gsm fsfi | #1 |
| hfs trial | #1 |
| compliance institutional guidelines | #1 |
| cipn trials | #1 |
| leap lymphedema | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| polyneuropathy allelic variability | #1 |
| antiserotonergic drug | #1 |
| feet oxaliplatin | #1 |
| gas menopause patient | #1 |
| preliminary promising data | #1 |
| bakplo | #1 |
| numbness scores | #1 |
| alliance a151724 | #1 |
| male megestrol megestrol | #1 |
| cipn development severity | #1 |
| uniscale qol baseline | #1 |
| hot flash | #1 |
| alliance study a221102 | #1 |
| rest psychostimulants | #1 |
| oral cryotherapy prevention | #1 |
| 22 nonestrogenic management | #1 |
| dronabinol megestrol acetate | #1 |
| deprivation symptoms | #1 |
| modalities cancer patients | #1 |
| pilot trials venlafaxine | #1 |
| week tamoxifen | #1 |
| antidepressant gabapentin | #1 |
| oral mucosa study | #1 |
| cipnsummarythere | #1 |
| hot flashes patients | #1 |
| preceding 2 months | #1 |
| receiving fluorouracil | #1 |
| adam vte | #1 |
| ncctg n08c1 | #1 |
| purpose hot | #1 |
| toxicity gabapentin | #1 |
| paresthesia peripheral | #1 |
| paclitaxel study arms | #1 |
| flashes week | #1 |
| nonhormonal agent | #1 |
| revisitation doc | #1 |
| qolconclusionsthe | #1 |
| newer antidepressants | #1 |
| acute pain syndrome | #1 |
| uncertain gbu | #1 |
| week hot | #1 |
| patients placebo pellet | #1 |
| snv rs9657362 | #1 |
| compassionate honesty | #1 |
| hot flash frequency | #1 |
| treatment cipn | #1 |
| leucovorin breast | #1 |
| patients underdescribers | #1 |
| flashes prostate | #1 |
| records adult patients | #1 |
| flashes objective | #1 |
| 5fuinduced ocular toxicity | #1 |
| dfs predictions adjuvant | #1 |
| flashes androgen | #1 |
| purposepaclitaxel | #1 |
| gene arhgef10 | #1 |
| populations neurologic humans | #1 |
| median δ qs | #1 |
| judicious tpn | #1 |
| hfs ulabtka | #1 |
| numeracy benefit | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| patients cancer anorexia | #1 |
| neuropathic pain difficulty | #1 |
| balance impairments patients | #1 |
| dronabinol combination | #1 |
| numbness hands | #1 |
| illness neuropathic symptoms | #1 |
| oral cryotherapy management | #1 |
| 95 neuropathic pain | #1 |
| loe prevention | #1 |
| a151408 | #1 |
| control hot flashes | #1 |
| eortc cipn | #1 |
| drowsiness unpleasant taste | #1 |
| decrease hot | #1 |
| olanzapine arm emesis | #1 |
| overview crci | #1 |
| studies cyproheptadine | #1 |
| subsequent chemotherapy cycles | #1 |
| chamomile mouthwash toxicity | #1 |
| hormonal ablation andropause | #1 |
| outcomes study points | #1 |
| ssc device prototype | #1 |
| placebo 30 points | #1 |
| alleviate hot | #1 |
| neoplasms climacteric | #1 |
| ctcae grade | #1 |
| tpn longterm survival | #1 |
| attribution treatment | #1 |
| toxicity ocular | #1 |
| attribution percentage | #1 |
| megestrol acetate weeks | #1 |
| oestrogen survivors | #1 |
| flaxseed bar | #1 |
| agents cyclohexanecarboxylic | #1 |
| n08ca association | #1 |
| topical keratolytic | #1 |
| aes placebo arm | #1 |
| arthralgia breast life | #1 |
| fsfi 95 | #1 |
| mouthwash placebo | #1 |
| sensory neuropathy symptoms | #1 |
| testosterone improvements | #1 |
| trust oncologists competence | #1 |
| bakplo placebo | #1 |
| gait testing patients | #1 |
| flashes venlafaxine | #1 |
| natural postural instability | #1 |
| 95 doxepin mouthwash | #1 |
| longitudinal continuation | #1 |
| symptoms cipn | #1 |
| accru trial | #1 |
| symptom intervention | #1 |
| alliance n08c1 | #1 |
| patients physical examinations | #1 |
| eortc cipn20 | #1 |
| 1 month appetite | #1 |
| placebo anecdotal observations | #1 |
| impaired postural control | #1 |
| intervention leap | #1 |
| pregenplus | #1 |
| ocular ice | #1 |
| women male megestrol | #1 |
| leap rom | #1 |
| attribution clinical trials | #1 |
| pilot trials citalopram | #1 |
| 5 weeks device | #1 |
| isae anthracycline | #1 |
| treatment alteration | #1 |
| n08cb | #1 |
| crc patients 95 | #1 |
| qolresultsfrom | #1 |
| placebo drowsiness | #1 |
| neuropathic symptoms breast | #1 |
| nonfluid weight gain | #1 |
| trial n00cb | #1 |
| accru study ru221408i | #1 |
| alopecia ocular toxicity | #1 |
| 30 points 95 | #1 |
| pregabalin paclitaxel | #1 |
| 81 patients patients | #1 |
| patients highdose interferon | #1 |
| neuropathy prevention | #1 |
| lymphedema incidence intervention | #1 |
| oestrogen hot flashes | #1 |
| alleviating hot | #1 |
| reducing hot | #1 |
| paclitaxel weekly cryotherapy | #1 |
| cachexia megestrol | #1 |
| initiation tpn | #1 |
| device 5 weeks | #1 |
| lymphedemafree rates groups | #1 |
| fourth treatment week | #1 |
| vaginal dehydroepiandrosterone | #1 |
| flaxseed hot flashes | #1 |
| altered sensory organization | #1 |
| relatedness treatment arms | #1 |
| positive indication prognosis | #1 |
| baseline fsfi score | #1 |
| doxepin mouthwash patients | #1 |
| cipn agents | #1 |
| cisplatin therapy cinv | #1 |
| ulabtka arm | #1 |
| supportive nsclc | #1 |
| postural instability chemotherapy | #1 |
| weeks hot flashes | #1 |
| sae δ − | #1 |
| aminobutyric acid hec | #1 |
| gabapentin baseline week | #1 |
| antineoplastic agents nrs | #1 |
| burden alopecia | #1 |
| management hot flashes | #1 |
| topic peripheral neuropathy | #1 |
| nonhormonal agents treatment | #1 |
| flashes quality | #1 |
| efficacy gabapentin | #1 |
| replacement testosterone andropause | #1 |
| oncologists competence | #1 |
| peripheral neuropathy | #1 |
| ulabtka hfs | #1 |
| authors 115 patients | #1 |
| flash scores | #1 |
| pilot trials efficacy | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| prtmethodsdata | #1 |
| time publication attitude | #1 |
| female services tpn | #1 |
| taxane treatment development | #1 |
| pain chemotherapy | #1 |
| bakplo symptoms | #1 |
| placebo arm gabapentin | #1 |
| suggestion toxicity | #1 |
| flashes common | #1 |
| 8week observation period | #1 |
| nociceptors putative mechanism | #1 |
| nonfluid bodyweights | #1 |
| patients subcutaneous testosterone | #1 |
| patients 10 range | #1 |
| vte recurrence enoxaparin | #1 |
| patients gabapentin | #1 |
| tools oncologists | #1 |
| patients spray product | #1 |
| underdescribing | #1 |
| rom leap | #1 |
| patients 25 micrograms | #1 |
| data clinical histories | #1 |
| acetate anorexia | #1 |
| effects limited efficacy | #1 |
| cachexia cyproheptadine | #1 |
| isaes | #1 |
| hot flash relief | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| data hot | #1 |
| balance gait testing | #1 |
| life qlqcipn20 | #1 |
| placebo arms percentage | #1 |
| 2007 guidelines guideline | #1 |
| baseline week gabapentin | #1 |
| infliximab cancer | #1 |
| chemotherapy regimen type | #1 |
| hot flash control | #1 |
| prognosis items | #1 |
| pharmacological targeting oct2 | #1 |
| rs2294039 | #1 |
| olanzapine projects vomiting | #1 |
| prevention oral cryotherapy | #1 |
| survival tpn initiation | #1 |
| safety progestational agents | #1 |
| purposehot | #1 |
| bupropion nicotine dependence | #1 |
| bellergal | #1 |
| nonhormonal | #1 |
| topic rectum surveys | #1 |
| patient followup studies | #1 |
| oral mucositis alopecia | #1 |
| discrepancies women | #1 |
| cachexia carcinoma life | #1 |
| mascc isoo guidelines | #1 |
| life leap | #1 |
| gabapentin antidepressant | #1 |
| efficacy agent | #1 |
| induced cipn | #1 |
| based chemotherapy isae | #1 |
| combination chemotherapy hec | #1 |
| megestrol acetate | #1 |
| underdescribers | #1 |
| flashes stellate | #1 |
| chemotherapy treatment chemotherapy | #1 |
| supportive cryotherapy | #1 |
| chemotherapy neuropathy | #1 |
| hec cisplatin therapy | #1 |
| cancerrelated fatigue interventions | #1 |
| hormone deprivation symptoms | #1 |
| background hot | #1 |
| cachexia trial | #1 |
| rs17683288 | #1 |
| nonhormonal hot | #1 |
| alliance n08ca | #1 |
| numerical analogue scale | #1 |
| recurrences clinical histories | #1 |
| cipn20 | #1 |
| doxepin mouthwash | #1 |
| phase iii evaluation | #1 |
| duloxetine response | #1 |
| adjuvant numeracy calculators | #1 |
| drug humans interferons | #1 |
| lymphedemafree rates | #1 |
| cancer hot | #1 |
| evidence cipn | #1 |
| placebo mouthwash | #1 |
| auc cryotherapy | #1 |
| 5fu adjuvant | #1 |
| n01c9 | #1 |
| managing hot flashes | #1 |
| peripheral neuropathy paclitaxel | #1 |
| breakthrough nausea patients | #1 |
| patients megestrol acetate | #1 |
| patients dfs predictions | #1 |
| treating hot | #1 |
| underdescribers weeks | #1 |
| progestational agents patients | #1 |
| stomatitis administration | #1 |
| oral cryotherapy patients | #1 |
| gabapentin aminobutyric acid | #1 |
| neoplasms placebos | #1 |
| prominent clinical problem | #1 |
| study stool samples | #1 |
| myalgias arthralgias | #1 |
| duloxetine response patients | #1 |
| chamomile mouthwash | #1 |
| cachexia dexamethasone | #1 |
| patientreported nasal symptoms | #1 |
| lymphedema hrqol outcomes | #1 |
| severe stomatitis | #1 |
| 12 months anticoagulation | #1 |
| acetate hot | #1 |
| treatment symptom intervention | #1 |
| hot flash score | #1 |
| topical cannabinoids | #1 |
| regional hypothermia burden | #1 |
| cinv neoplasms vomiting | #1 |
| study dmc assay | #1 |
| education lymphedema education | #1 |
| understanding potential benefits | #1 |
| score baseline values | #1 |
| current trial | #1 |
| amines antidepressive | #1 |
| patients ulabtka | #1 |
| 137 patients cycle | #1 |
| treatments modalities | #1 |
| paclitaxel acute | #1 |
| antidepressive agents gamma | #1 |
| cipn clinical trial | #1 |
| flashes gabapentin | #1 |
| prominent toxicity | #1 |
| n00cb | #1 |
| vaginal cytology women | #1 |
| fsfi udi | #1 |
| difficulty neuropathic pain | #1 |
| adam vte trial | #1 |
| 95 increased difficulty | #1 |
| 5 methylphenidate | #1 |
| prestudy hypothesis | #1 |
| life cipn | #1 |
| baseline week followup | #1 |
| points diphenhydramine | #1 |
| 2 study arms | #1 |
| randomized study lymphedema | #1 |
| ganglion surveys humans | #1 |
| established cipn | #1 |
| agents cipn | #1 |
| increased difficulty patients | #1 |
| qol reported difficulty | #1 |
| isae patients | #1 |
| daily questionnaires | #1 |
| difference cipn20 scores | #1 |
| cipn topical gel | #1 |
| cipn adult | #1 |
| discrepancies clinicians assessment | #1 |
| favor placebo | #1 |
| pharmacologic therapeutics | #1 |
| symptoms feet | #1 |
| bridging editorial | #1 |
| hot flashes acceptability | #1 |
| iii double | #1 |
| physical consequences cipn | #1 |
| flashes women | #1 |
| highdose melphalan intervention | #1 |
| papsmethodspatients | #1 |
| toxicities opioids | #1 |
| cryotherapy mucositis | #1 |
| gabapentin hot flashes | #1 |
| cipn20 data | #1 |
| anthracycline data | #1 |
| cyproheptadine appetite | #1 |
| doubleblinded manner | #1 |
| darbepoetin alfa head | #1 |
| cachexia cancer anorexia | #1 |
| oncologists competence 95ci | #1 |
| disease patient factors | #1 |
| stomatitis scores | #1 |
| placebo 15 points | #1 |
| megestrol acetate patients | #1 |
| humans ganglion surveys | #1 |
| compliance institutional guideline | #1 |
| flashes pilot | #1 |
| dmc mutations | #1 |
| paclitaxel coasting phenomenon | #1 |
| male megestrol life | #1 |
| topical cannabinoids patients | #1 |
| pregabalin paps | #1 |
| udi δ − | #1 |
| burning pain | #1 |
| therapy hot | #1 |
| flashes treatment | #1 |
| hot flash data | #1 |
| suggested gabapentin | #1 |
| tools hypothetical scenarios | #1 |
| suggestion oral cryotherapy | #1 |
| dfs 5fu | #1 |
| δ − 95 | #1 |
| cryotherapy auc | #1 |
| dmc samples | #1 |
| hot flashes women | #1 |
| acute symptoms cycle | #1 |
| minocycline cipn | #1 |
| centrally active agent | #1 |
| authors 30 minutes | #1 |
| life illness tetracycline | #2 |
| 3 months bupropion | #2 |
| venlafaxine gabapentin | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| stage disease 5fu | #2 |
| real patients treatment | #2 |
| nonestrogenic hot | #2 |
| original report mometasone | #2 |
| anorexia antineoplastic | #2 |
| stat itching | #2 |
| fosaprepitant patients | #2 |
| mmf itching | #2 |
| questionnaires antineoplastic agents | #2 |
| type chemotherapy drug | #2 |
| piroxantrone women | #2 |
| ncctg n10c1 | #2 |
| shark cartilage patients | #2 |
| conclusions original report | #2 |
| npy anorexia cholecystokinin | #2 |
| scrambler therapy treatment | #2 |
| predictors disagreement | #2 |
| baseline week day | #2 |
| dhea vaginal symptoms | #2 |
| guidelines recommendation | #2 |
| scrambler | #2 |
| qol crc | #2 |
| stomatitis women | #2 |
| coriat | #2 |
| hot flash diary | #2 |
| patients cipn | #2 |
| neuropathy paclitaxel | #2 |
| trial baseline week | #2 |
| females cessation treatment | #2 |
| tingling patients | #2 |
| docetaxel serum concentrations | #2 |
| disagreement patients | #2 |
| cold items 71 | #2 |
| cipn20 factor analysis | #2 |
| symptomatic cipn | #2 |
| rcts preventive therapies | #2 |
| conceppt | #2 |
| appearing pilot data | #2 |
| patients daily mmf | #2 |
| neoplasms double | #2 |
| patients 120k arm | #2 |
| suggested agents | #2 |
| 95 indirect estimates | #2 |
| hot flash trials | #2 |
| oxaliplatin hands | #2 |
| pregabalin arms | #2 |
| skindex16 ctcae | #2 |
| detection screenrelevant neoplasms | #2 |
| 5fubased chemotherapy mucositis | #2 |
| n01c4 | #2 |
| sulfate prevent | #2 |
| women hot flashes | #2 |
| scrambler therapy management | #2 |
| induced arthralgias | #2 |
| 01 mmf | #2 |
| cachexia pentoxifylline | #2 |
| time toxt approach | #2 |
| infertility ovarian failure | #2 |
| design considerations recommendations | #2 |
| experience hot flashes | #2 |
| physicians kps | #2 |
| weight concerns 26 | #2 |
| study arms quality | #2 |
| tens global impression | #2 |
| mometasone surveys | #2 |
| antidepressants hot | #2 |
| folfox alliance | #2 |
| cipn cancer survivors | #2 |
| hemoccultsensa sdt2 | #2 |
| 4 treatment weeks | #2 |
| product hot flashes | #2 |
| prevent radiation | #2 |
| singleagent megestrol acetate | #2 |
| pilocarpine vaginal dryness | #2 |
| flashes placebo | #2 |
| randomized receive | #2 |
| monthly intervals appetite | #2 |
| detection dna markers | #2 |
| toxicity profiles time | #2 |
| pilot citalopram | #2 |
| disagreement increased risk | #2 |
| patients receiving fluorouracil | #2 |
| vitamin hot | #2 |
| methylphenidate cancer | #2 |
| neuropathy caused | #2 |
| evaluating venlafaxine | #2 |
| failure prior chemotherapy | #2 |
| 16 sdt2 | #2 |
| tamoxifen percentage reduction | #2 |
| vitamin hot flashes | #2 |
| improvement hot flashes | #2 |
| moderate correlations ≤ | #2 |
| anorexia severity | #2 |
| local antineoplastic agents | #2 |
| fsfi score baseline | #2 |
| cancerassociated wasting | #2 |
| cipn cases | #2 |
| treatment arm mmf | #2 |
| skindex16 itching | #2 |
| 34—vitamin | #2 |
| reduce hot | #2 |
| npy levels groups | #2 |
| 95 oral placebo | #2 |
| circulating concentrations npy | #2 |
| hemoccultsensa hemoccult | #2 |
| tamoxifen medications | #2 |
| desipramine hot flashes | #2 |
| previous hot flashes | #2 |
| tens 2 weeks | #2 |
| cipn clinical | #2 |
| lmwh arms | #2 |
| supplementary n03cb | #2 |
| study arms | #2 |
| anemia caa | #2 |
| dronabinoltreated patients | #2 |
| appetite dissent disputes | #2 |
| pa outcomes pros | #2 |
| acttionconsortium | #2 |
| usual breathing | #2 |
| week breast cancer | #2 |
| pilocarpine vaginal | #2 |
| clinical trials n9741 | #2 |
| tingling shooting | #2 |
| daily mmf radiotherapy | #2 |
| appetite cachexia | #2 |
| hemoccultsensa sdt1 | #2 |
| hot flash management | #2 |
| irox folfox auc | #2 |
| placebo combination therapy | #2 |
| nonhormonal management | #2 |
| ncctg trial | #2 |
| rash incidence severity | #2 |
| fatigue improvement methylphenidate | #2 |
| hot flash frequencies | #2 |
| reducing chemotherapy | #2 |
| patients treating institution | #2 |
| advancedstage cancer | #2 |
| folfox symptoms | #2 |
| induced peripheral | #2 |
| oxybutynin women | #2 |
| descriptive manner | #2 |
| pain ≥4 10 | #2 |
| ≤ moderate correlations | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| eortc qlqcipn20 | #2 |
| 432 smokers treatment | #2 |
| life aimss | #2 |
| gabapentin 4 weeks | #2 |
| day baseline week | #2 |
| study arms conclusions | #2 |
| shark cartilage placebo | #2 |
| weekly hf score | #2 |
| standard arm rate | #2 |
| pruritus pros | #2 |
| time randomized study | #2 |
| neuropathy cipn | #2 |
| treatment alterations | #2 |
| vte recurrence dalteparin | #2 |
| tamoxifen metabolism evidence | #2 |
| fluoxymesterone treatment | #2 |
| humans postmenopause pregabalin | #2 |
| hot flashes citalopram | #2 |
| breakthrough cinv | #2 |
| anabolic corticosteroid appetite | #2 |
| venlafaxine treatment 75 | #2 |
| numeracy prognosis | #2 |
| 75 49 venlafaxine | #2 |
| preventive therapies cipn | #2 |
| leucovorin women | #2 |
| hot flash quality | #2 |
| levetiracetam 4 weeks | #2 |
| patients shark cartilage | #2 |
| injections hot flashes | #2 |
| paclitaxel chronic neuropathy | #2 |
| positive doseresponse | #2 |
| allopurinol mouthwash | #2 |
| hot flashes data | #2 |
| dosing zoledronic | #2 |
| historic controls npy | #2 |
| depomedroxyprogesterone | #2 |
| subsequent mucositis | #2 |
| cpmp scrambler therapy | #2 |
| tamoxifenassociated hot flashes | #2 |
| data relative benefits | #2 |
| advanced cancer anorexia | #2 |
| sdt2 hemoccult | #2 |
| target doses placebo | #2 |
| manuscript “use | #2 |
| conclusions sunscreen | #2 |
| cancerassociated anorexia | #2 |
| ductal mometasone furoate | #2 |
| magnesium oxaliplatin | #2 |
| stat erythema | #2 |
| flashes citalopram | #2 |
| oxaliplatin doses trends | #2 |
| 108±11 | #2 |
| megestrol acetate dexamethasone | #2 |
| folfox auc p0·0001 | #2 |
| placebo situ carcinoma | #2 |
| peripheral neuropathy cipn | #2 |
| placebo oxybutynin doses | #2 |
| cipn peripheral neuropathy | #2 |
| glutathione prevention | #2 |
| global impression life | #2 |
| cipn antineoplastic agents | #2 |
| postural instability individuals | #2 |
| screenrelevant neoplasms 16 | #2 |
| ecog nutrition score | #2 |
| egfr inhibitor tetracycline | #2 |
| colonoscopically normal patients | #2 |
| smokers nicotine inhaler | #2 |
| glutamine placebo preparation | #2 |
| arms conclusions | #2 |
| improvement hot | #2 |
| shark cartilage product | #2 |
| placebo bar | #2 |
| oral iron 46 | #2 |
| gabapentin symptoms | #2 |
| poor qol 95 | #2 |
| aprepitan | #2 |
| ferric gluconate darbepoetin | #2 |
| sensitivity cold items | #2 |
| flash diary | #2 |
| cohosh treatment | #2 |
| oxybutynin doses placebo | #2 |
| appetite dissent | #2 |
| clinically deficient fatigue | #2 |
| postmenopausal women previous | #2 |
| feet 18 months | #2 |
| autonomic scales | #2 |
| n06c4 | #2 |
| decreasing stomatitis | #2 |
| paclitaxel induced | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| placebo arms women | #2 |
| sunscreen arms | #2 |
| receive parenteral | #2 |
| antidepressant hot flashes | #2 |
| 40000 40k arm | #2 |
| ctcae differences | #2 |
| lessons cipn | #2 |
| patients oxybutynin doses | #2 |
| cisplatin polymerase inhibitors | #2 |
| indirect comparison apixaban | #2 |
| intermediate term efficacy | #2 |
| randomized study mometasone | #2 |
| life cipn20 | #2 |
| worse survivorship | #2 |
| trials suggested | #2 |
| single snv | #2 |
| cipn cancer treatment | #2 |
| 120 arm | #2 |
| patients 40k arm | #2 |
| 120000 epoetin alfa | #2 |
| cipn20 scores | #2 |
| treating chemotherapy | #2 |
| lamotrigine neuropathic symptoms | #2 |
| duloxetine hydrochloride humans | #2 |
| 5fuinduced mucositis | #2 |
| management genitourinary symptoms | #2 |
| 150 groups patients | #2 |
| treatment target doses | #2 |
| trials newer antidepressants | #2 |
| treatment cycles cycle | #2 |
| sdt1 hemoccult | #2 |
| palliative communications | #2 |
| guaninemethyltransferase | #2 |
| original report time | #2 |
| data gabapentin | #2 |
| vte recurrence doacs | #2 |
| ctcae pruritus | #2 |
| patients chemotherapyassociated anemia | #2 |
| woman quality | #2 |
| stomatitis sex | #2 |
| central cancer | #2 |
| hot flashes pregabalin | #2 |
| life venlafaxine hydrochloride | #2 |
| evaluate weight | #2 |
| patients adjuvant 5fu | #2 |
| flash studies | #2 |
| 46 adenomas 1 | #2 |
| lmwh arms 7 | #2 |
| mucositis 5fubased chemotherapy | #2 |
| patients difluoromethylornithine | #2 |
| placebo breast radiotherapy | #2 |
| citalopram cyclohexanols humans | #2 |
| average stomatitis sex | #2 |
| kps nutrition scores | #2 |
| week baseline week | #2 |
| day study week | #2 |
| life scrambler therapy | #2 |
| placebo pregabalin treatments | #2 |
| receiving megestrol | #2 |
| 15 points 95 | #2 |
| differences mometasone | #2 |
| chemotherapy peripheral neuropathy | #2 |
| phytogenic female humans | #2 |
| n03cb | #2 |
| breast cancer venlafaxine | #2 |
| study treatment citalopram | #2 |
| older age bupropion | #2 |
| 135±19 | #2 |
| topic estrogen | #2 |
| cycle chronic neurotoxicity | #2 |
| life treatment weeks | #2 |
| doses megestrol | #2 |
| hot flashes aprepitant | #2 |
| humans citalopram cyclohexanols | #2 |
| cck8 anorexia severity | #2 |
| intervention 18 months | #2 |
| hot flash studies | #2 |
| coumarin placebo | #2 |
| 40k arm | #2 |
| longitudinal studies postmenopause | #2 |
| established chemotherapy | #2 |
| trial acetate doses | #2 |
| infliximab docetaxel | #2 |
| dronabinol combination therapy | #2 |
| substantial hot flashes | #2 |
| oral megestrol | #2 |
| increased risk cipn | #2 |
| life cancerrelated fatigue | #2 |
| versus megestrol | #2 |
| treatment minority smokers | #2 |
| cdf score | #2 |
| acknowledged loss | #2 |
| placebo vaginal dryness | #2 |
| screenrelevant neoplasms | #2 |
| cycle folfox | #2 |
| 1 oral megestrol | #2 |
| topical aged antimetabolites | #2 |
| cachexia decision | #2 |
| inadequate benefit | #2 |
| tetracycline rash incidence | #2 |
| women rom | #2 |
| hot flashes bupropion | #2 |
| adjuvant 5fu models | #2 |
| nicotine inhaler bupropion | #2 |
| 14 hot flashes | #2 |
| folfox auc analysis | #2 |
| epoetin alfa 40000 | #2 |
| illness tetracycline egfr | #2 |
| postchemotherapy rheumatism | #2 |
| hot flashes efficacy | #2 |
| chemotherapyassociated anemia caa | #2 |
| 120k arm patients | #2 |
| week black cohosh | #2 |
| prevalence weight concerns | #2 |
| cachexia acetate | #2 |
| cipn paclitaxel | #2 |
| n0993 | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| nonestrogenic therapies | #2 |
| placebo hf frequency | #2 |
| 46 screenrelevant neoplasms | #2 |
| weekly epoetin | #2 |
| life 4week intervention | #2 |
| efficacy scrambler therapy | #2 |
| citalopram hot flashes | #2 |
| pregabalin treatments placebo | #2 |
| 7 control arms | #2 |
| sdt2 | #2 |
| 49 venlafaxine | #2 |
| dronabinol versus | #2 |
| treatment baseline week | #2 |
| dhea 4 weeks | #2 |
| starting tamoxifen | #2 |
| scrambler therapy tens | #2 |
| alliance folfox | #2 |
| pregabalin hot flashes | #2 |
| induced peripheral neuropathy | #2 |
| venlafaxine control | #2 |
| prevent paclitaxel | #2 |
| cipn primary outcomes | #2 |
| hemoccultsensa sensitivity | #2 |
| bupropion nicotine inhaler | #2 |
| alternative treatment regimen | #2 |
| surveys repeated measures | #2 |
| women stomatitis | #2 |
| participants 3 stools | #2 |
| anthrapyrazoles piroxantrone | #2 |
| appetite improvement | #2 |
| anthraquinones agents breast | #2 |
| cipn interventions | #2 |
| lvef 1000 | #2 |
| anabolic corticosteroid treatment | #2 |
| dermatitis symptom evolution | #2 |
| thiophenes treatment life | #2 |
| hemoccultsensa detection | #2 |
| time toxt analysis | #2 |
| kps nutrition score | #2 |
| control arms rate | #2 |
| mometasone cream | #2 |
| anabolic corticosteroid | #2 |
| months randomized | #2 |
| natural paps | #2 |
| 40k arm 120000 | #2 |
| infliximab 5 day | #2 |
| outcome measures ctcae | #2 |
| treatment breakthrough cinv | #2 |
| therapy hot flashes | #2 |
| 16 hemoccult | #2 |
| trial suggestion | #2 |
| patient‐physician disagreement | #2 |
| treatment smoking abstinence | #2 |
| provider assessed | #2 |
| iii randomized | #2 |
| middle aged survivors | #2 |
| dna markers participants | #2 |
| hf frequency placebo | #2 |
| starting tamoxifen women | #2 |
| declining qol | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| treatment aprepitant | #2 |
| evaluating gabapentin | #2 |
| life venlafaxine | #2 |
| locoregional event | #2 |
| qol hb increment | #2 |
| nutrition scores 95 | #2 |
| patients black cohosh | #2 |
| treatment week placebo | #2 |
| incidence severity stomatitis | #2 |
| scrambler therapy | #2 |
| chronic chemotherapy | #2 |
| study arms tetracycline | #2 |
| patients monthly intervals | #2 |
| cipn prevention trials | #2 |
| 800 liquid suspension | #2 |
| real real patients | #2 |
| aprepitant 4 weeks | #2 |
| pilocarpine arms | #2 |
| mometasone time | #2 |
| 120k arm | #2 |
| study n08cb alliance | #2 |
| “use vitamin | #2 |
| symptoms surveys | #2 |
| dalteparin lowest risk | #2 |
| 979254 | #2 |
| cipn | #2 |
| time ncctg alliance | #2 |
| subject global impression | #2 |
| hot flashes humans | #2 |
| nutrition scores physicians | #2 |
| day average pain | #2 |
| sdt2 sdt1 | #2 |
| patients olanzapine arm | #2 |
| dexamethasone fluoxymesterone | #2 |
| newer antidepressants trials | #2 |
| symptoms skin toxicity | #2 |
| nutrition score disagreement | #2 |
| survival 3915 patients | #2 |
| cipn cohort | #2 |
| 80 anorexia | #2 |
| oral megestrol acetate | #3 |
| ctcae grading arms | #3 |
| patients baseline week | #3 |
| drug toxicity patients | #3 |
| traditional ctcae | #3 |
| paps dose | #3 |
| inhibitorinduced rash | #3 |
| hgpin chemoprevention trial | #3 |
| data ginseng | #3 |
| gabapentin management | #3 |
| oxaliplatin primary endpoint | #3 |
| corticosteroid medications | #3 |
| epoetin alfa hgb | #3 |
| 51 female age | #3 |
| hormonal ablation | #3 |
| neoplasms vomiting | #3 |
| cipn snv | #3 |
| qlqcipn20 traditional ctcae | #3 |
| delayed treatment arm | #3 |
| frequency hot | #3 |
| n08ca n08cb study | #3 |
| gwas mayo clinic | #3 |
| ” numbness | #3 |
| prevent epidermal | #3 |
| qol hgb | #3 |
| eventual sensory patients | #3 |
| topic mayo clinic | #3 |
| mcbdr primary endpoint | #3 |
| measures peripheral | #3 |
| burning pain patients | #3 |
| tamoxifen fluoxetine | #3 |
| ctpm experts | #3 |
| cmt genes oxaliplatin | #3 |
| data pilot trials | #3 |
| 3 weeks 80k | #3 |
| week venlafaxine therapy | #3 |
| flutamide hgpin | #3 |
| hot flashes trial | #3 |
| interventions cancerrelated fatigue | #3 |
| hgb rbc transfusions | #3 |
| depression somnolence | #3 |
| chemotherapy‐associated anemia | #3 |
| middle aged pilot | #3 |
| chemotherapyassociated anemia | #3 |
| relationship response rate | #3 |
| hemoccult hemoccultsensa | #3 |
| baseline treatment day | #3 |
| mouthwash patients | #3 |
| patient completed | #3 |
| starting letrozole | #3 |
| oxaliplatinbased therapy | #3 |
| preventing peripheral | #3 |
| weekly arm differences | #3 |
| 20 calories | #3 |
| n08ca paclitaxel | #3 |
| real day | #3 |
| primary endpoint gwas | #3 |
| week chemotherapy dose | #3 |
| average severity | #3 |
| selfreport ctcae grading | #3 |
| rash prevention | #3 |
| life eortc qlq | #3 |
| topical ceramides | #3 |
| neuropathy trials | #3 |
| shooting burning pain | #3 |
| placebo breast | #3 |
| bit hands | #3 |
| minocycline prevention | #3 |
| projects prospective | #3 |
| cachexia decision humans | #3 |
| patients cancerassociated wasting | #3 |
| asco surveillance | #3 |
| follow fsfi | #3 |
| rash conclusions | #3 |
| 40000 units | #3 |
| cyclohexanecarboxylic acids | #3 |
| egfr inhibitor patients | #3 |
| male megestrol | #3 |
| vitamin prevention | #3 |
| life antineoplastic agents | #3 |
| placebo prostate adenocarcinoma | #3 |
| delayed zoledronic | #3 |
| management cancer cachexia | #3 |
| alfa compared | #3 |
| qlqcipn20 scores | #3 |
| epoetintreated patients study | #3 |
| pilot evaluation gabapentin | #3 |
| repeated measures analyses | #3 |
| ctcae pros | #3 |
| vaginal dhea | #3 |
| patients lidocaine patch | #3 |
| anorexia anorexia appetite | #3 |
| placebo preparation | #3 |
| genetic factors patients | #3 |
| thromboembolism secondary | #3 |
| additional 4 weeks | #3 |
| pros differences | #3 |
| aminobutyric acid gabapentin | #3 |
| female gabapentin | #3 |
| relationship numbness | #3 |
| advanced cancer standard | #3 |
| egfr inhibitorinduced rash | #3 |
| undergoing androgen ablation | #3 |
| epoetintreated patients | #3 |
| genetic predictors paclitaxel | #3 |
| upfront arm | #3 |
| 95 udi | #3 |
| hot flashes placebo | #3 |
| dalteparin vte | #3 |
| cancer patients drugs | #3 |
| chemotherapy gabapentin | #3 |
| radiation‐induced mucositis | #3 |
| trials n9741 | #3 |
| apixaban lowest risk | #3 |
| n05c4 | #3 |
| snv cmtassociated genes | #3 |
| ctcae grades patients | #3 |
| eightyone randomized women | #3 |
| life dronabinol | #3 |
| cipn biological targets | #3 |
| patients scrambler therapy | #3 |
| trial bmd | #3 |
| pts stage iii | #3 |
| stomatitis sucralfate | #3 |
| neurotoxic chemotherapy cipn | #3 |
| 10 weeks therapy | #3 |
| reported rash | #3 |
| fluoxetine arm | #3 |
| oxaliplatininduced neuropathy | #3 |
| general subscale mfsisf | #3 |
| n03cc | #3 |
| months bupropion | #3 |
| thirdline hormonal therapy | #3 |
| methodologic lessons | #3 |
| receive placebo | #3 |
| trials newer | #3 |
| purposefosaprepitant | #3 |
| ssc device | #3 |
| longitudinal adverse | #3 |
| experience greater | #3 |
| rash symptoms | #3 |
| 95 40 points | #3 |
| iii evaluation | #3 |
| iii controlled | #3 |
| bivariate construct | #3 |
| patients antiemetic | #3 |
| epoetintreated patients incidence | #3 |
| survivors gsm | #3 |
| classic sums | #3 |
| survival cancerassociated wasting | #3 |
| cartilage shark | #3 |
| combinationtreated arms | #3 |
| mastectomy rates | #3 |
| paps scores | #3 |
| chronic neuropathy patients | #3 |
| patients upfront arm | #3 |
| chlorhexidine mouthwash | #3 |
| neuropathy chemotherapy | #3 |
| qol placebotreated patients | #3 |
| carboplatin gwas | #3 |
| ≤−20 | #3 |
| feet 15 | #3 |
| baseline general subscale | #3 |
| patients cyproheptadine | #3 |
| recommendations dietary counseling | #3 |
| bacterial agents life | #3 |
| incurable cancers | #3 |
| hemoccultsensa | #3 |
| study antidepressive agents | #3 |
| study population mcbdr | #3 |
| survival epa | #3 |
| evidence prostate adenocarcinoma | #3 |
| crossover methodology | #3 |
| toxicities selfreport | #3 |
| cipn mcbdr population | #3 |
| cvte | #3 |
| sham acupuncture week | #3 |
| prophylactic tetracycline | #3 |
| mpa single dose | #3 |
| snv charcotmarietooth disease | #3 |
| rash study arms | #3 |
| completed diaries | #3 |
| neurotoxic chemotherapies | #3 |
| controlled double | #3 |
| methylphenidate patients | #3 |
| intravenous calcium magnesium | #3 |
| cmt gene | #3 |
| fasting chemotherapy | #3 |
| experts cipn | #3 |
| life hospice patients | #3 |
| ginseng crf | #3 |
| physiologic pilot | #3 |
| questionnaires syndrome paclitaxel | #3 |
| baseline hot | #3 |
| oncology colorectal | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| centrally active agents | #3 |
| paps scores dose | #3 |
| asco guideline management | #3 |
| epa combinationtreated arms | #3 |
| clonidine randomized trials | #3 |
| “use | #3 |
| controls singleton snv | #3 |
| etanercept current trial | #3 |
| mfsisf 4 weeks | #3 |
| chemotherapy increases | #3 |
| numeracy patients | #3 |
| patients paps scores | #3 |
| qlqcipn20 | #3 |
| ginseng arm | #3 |
| genetic predictors cipn | #3 |
| chemotherapy induced | #3 |
| tingling burning pain | #3 |
| patients chemotherapy cycle | #3 |
| subcutaneous weekly | #3 |
| mucositis scores | #3 |
| mcbdr | #3 |
| oxaliplatin cipn | #3 |
| n08cx | #3 |
| purposeoxaliplatin | #3 |
| osteoporosis osteopenia letrozole | #3 |
| acute neuropathy | #3 |
| cipn n08cx population | #3 |
| upfront treatment arm | #3 |
| hands burning pain | #3 |
| cipn ctpm | #3 |
| combinationtreated arms survival | #3 |
| blind trial | #3 |
| pilot trial pregabalin | #3 |
| median δ | #3 |
| treatment bother | #3 |
| cyproheptadine patients | #3 |
| toxicity agents | #3 |
| dhea hot flashes | #3 |
| canada collaborative effort | #3 |
| cmtassociated genes | #3 |
| cipn cmtassociated genes | #3 |
| cipn evidence | #3 |
| cold items | #3 |
| centric decision | #3 |
| 1 month cytokines | #3 |
| acetate treated | #3 |
| dietician | #4 |
| placebo hot | #4 |
| nonestrogenic | #4 |
| suggested efficacy | #4 |
| calgb 70305 | #4 |
| hfs quality | #4 |
| anorectic cancer patients | #4 |
| 40000 | #4 |
| bupropion 3 | #4 |
| backgroundhistorically | #4 |
| breast medical oncologists | #4 |
| ctx odx | #4 |
| toxt analysis | #4 |
| control hot | #4 |
| placebo arms | #4 |
| chronic neuropathy | #4 |
| risk reduction therapy | #4 |
| oxybutynin placebo | #4 |
| odc activity mice | #4 |
| parenteral iron | #4 |
| paced breathing | #4 |
| therapy aimss | #4 |
| recommended endorsement | #4 |
| topic survivors | #4 |
| 6 months bupropion | #4 |
| rash incidence | #4 |
| followup surveillance protocol | #4 |
| weekly toxicity | #4 |
| benefits adjuvant | #4 |
| publication antiemetics humans | #4 |
| recommendation ctx | #4 |
| symptoms individual patients | #4 |
| doubleblind manner | #4 |
| hgpin antineoplastic agents | #4 |
| based chemotherapy severity | #4 |
| appetite stimulation | #4 |
| numbness toes | #4 |
| bupropion 3 months | #4 |
| women greater toxicity | #4 |
| controls imbalance | #4 |
| anorexia weight | #4 |
| 95 oral iron | #4 |
| logistic regression incidence | #4 |
| baseline fatigue survival | #4 |
| aged mouthwashes | #4 |
| endorsed treatment | #4 |
| outcomes olanzapine | #4 |
| flash frequency | #4 |
| severity sexes | #4 |
| general subscale | #4 |
| fluorouracilbased chemotherapy | #4 |
| 3915 patients | #4 |
| treatment cancer anorexia | #4 |
| single dose venlafaxine | #4 |
| 1093 women | #4 |
| ais biomarkers | #4 |
| severe stomatitis leukopenia | #4 |
| cachexia purpose | #4 |
| odx ctx | #4 |
| aimss | #4 |
| measurable metastatic disease | #4 |
| qol baseline fatigue | #4 |
| to100 | #4 |
| cco guideline followup | #4 |
| 900 dose | #4 |
| prominent problem | #4 |
| therapy oncologists | #4 |
| arm breast neoplasms | #4 |
| hot flashes therapy | #4 |
| weight loss syndrome | #4 |
| major doselimiting toxicity | #4 |
| based chemotherapy women | #4 |
| doxepin female head | #4 |
| odc odc activity | #4 |
| additional meta analysis | #4 |
| inhibitor induced | #4 |
| colorectal cancer asco | #4 |
| gabapentin day | #4 |
| flaxseed placebo | #4 |
| day paroxetine | #4 |
| predictors duloxetine response | #4 |
| mastectomy rates patients | #4 |
| qol performance score | #4 |
| hemoccult | #4 |
| or1 year | #4 |
| receive oral | #4 |
| loss syndrome | #4 |
| cancer acute vte | #4 |
| guidelines oral | #4 |
| secondary vte prevention | #4 |
| iron arm | #4 |
| hot flashes week | #4 |
| trpa1 cisplatin | #4 |
| doac dalteparin | #4 |
| cipn20 ctcae | #4 |
| survivors hot | #4 |
| egfr inhibitor rash | #4 |
| administration parp inhibitor | #4 |
| cutaneous electrostimulation | #4 |
| apr dex | #4 |
| rash study | #4 |
| anorexia cholecystokinin | #4 |
| addition letrozole | #4 |
| achievements ncctg | #4 |
| daily baseline | #4 |
| oral cavity mucosa | #4 |
| chemotherapy‐induced peripheral | #4 |
| appetite quality | #4 |
| surgery lymphedema | #4 |
| intrapatient difference | #4 |
| vaginal assessment scale | #4 |
| nonabsorbable antibiotic | #4 |
| nsclc trials | #4 |
| hec cisplatin | #4 |
| tpn initiation | #4 |
| oral cryotherapy mucositis | #4 |
| treatment ncctg | #4 |
| aapro | #5 |
| neoplasms compared | #5 |
| additional 8 weeks | #5 |
| study dmc | #5 |
| tools numeracy | #5 |
| progestational agent | #5 |
| mucositis caused | #5 |
| intravenous calcium | #5 |
| vasomotor hot flashes | #5 |
| questionnaires pregabalin | #5 |
| cipn effects | #5 |
| sham real | #5 |
| current trial patients | #5 |
| grade model estimates | #5 |
| patients lmwh injections | #5 |
| neuropathy acute | #5 |
| 3 stools | #5 |
| cindices ajcc | #5 |
| fosaprepitant prevention | #5 |
| cancerrelated fatigue patients | #5 |
| models ttr | #5 |
| treating postmenopausal | #5 |
| numeracy online clinical | #5 |
| ajcc version staging | #5 |
| discontinuation aimss | #5 |
| receiving paclitaxel | #5 |
| race ttr | #5 |
| digital melt | #5 |
| ajcc external validation | #5 |
| difference control arm | #5 |
| oxantrazole | #5 |
| ttr cindices | #5 |
| 5fu trials | #5 |
| pain scores dose | #5 |
| olanzapine arm | #5 |
| trial gabapentin | #5 |
| epa supplement | #5 |
| colorectal cancer society | #5 |
| iron oral | #5 |
| subsets treatment benefits | #5 |
| flashes data | #5 |
| trials lessons | #5 |
| death communication humans | #5 |
| cancer anorexia | #5 |
| ttr variables | #5 |
| acetate neoplasms | #5 |
| crc cancers | #5 |
| gabapentin trial | #5 |
| cipn numbness | #5 |
| cisplatin ganglia | #5 |
| reduce chemotherapy | #5 |
| life epa | #5 |
| trials cytotoxic chemotherapy | #5 |
| reported hot | #5 |
| cumulative neurotoxicity | #5 |
| physicians predictive ttr | #5 |
| cipn participants | #5 |
| genetic quality life | #5 |
| nodal status grade | #5 |
| ttr ajcc | #5 |
| rectal cancer surveillance | #5 |
| acetate neoplasms quality | #5 |
| centrally active | #5 |
| mucositis allopurinol | #5 |
| colorectal cancer surveillance | #5 |
| libido | #5 |
| trial hot | #5 |
| postsurgical neuropathic | #5 |
| cancer survivors symptoms | #5 |
| agents basis | #5 |
| ajcc tools | #5 |
| nutrition scores | #5 |
| groups leptin concentrations | #5 |
| neoplasm diagnostic tests | #5 |
| life lmwh | #5 |
| fiftynine percent | #5 |
| 3 patients 4 | #5 |
| induced stomatitis | #5 |
| appetite enhancement | #5 |
| women 5fu | #5 |
| trial developed | #5 |
| editor manuscript | #5 |
| treatment benefits sex | #5 |
| patient outcomes numeracy | #5 |
| placebo exposed | #5 |
| acetate placebo | #5 |
| medical oncology outpatients | #5 |
| physicianreported | #5 |
| impaired postural | #5 |
| hb increment | #5 |
| kps ecog | #5 |
| higher drug doses | #5 |
| major outcome measure | #5 |
| cachexia anorexia | #5 |
| odx | #5 |
| disputes female humans | #5 |
| cipnrelated symptoms | #5 |
| neuropeptide leptin | #5 |
| numeracy tools | #5 |
| fluoxymesterone patients | #5 |
| neuropathic pain qol | #5 |
| nodal status stage | #5 |
| bone loss osteopenia | #5 |
| combination electroacupuncture | #5 |
| ongoing clinical trial | #5 |
| cyclohexanecarboxylic | #5 |
| gabapentin patients | #5 |
| crc cancer types | #5 |
| olanzapine prevention | #6 |
| cancerrelated fatigue life | #6 |
| pharmaceutic aged aged | #6 |
| highly emetogenic chemotherapy | #6 |
| bf qol | #6 |
| placebo arm patients | #6 |
| north central | #6 |
| predictive illness surveys | #6 |
| neurological safety | #6 |
| methylo | #6 |
| hrqol breast neoplasms | #6 |
| studies vomiting | #6 |
| 5fubased chemotherapy | #6 |
| data supporting | #6 |
| mri trends | #6 |
| cipn treatment | #6 |
| 5fu folfox | #6 |
| longacting methylphenidate | #6 |
| megestrol | #6 |
| 4week intervention | #6 |
| intervention lymphedema | #6 |
| nonanthracycline chemotherapy | #6 |
| severity data | #6 |
| her2directed therapy | #6 |
| induced sensory | #6 |
| participants sham acupuncture | #6 |
| smoking abstinence rates | #6 |
| selective poly | #6 |
| apixaban cancer patients | #6 |
| sensory scale | #6 |
| placebo hot flashes | #6 |
| nci ctcae | #6 |
| daily diary questionnaires | #6 |
| death kps | #6 |
| imidazoles letrozole | #6 |
| inhaler bupropion | #6 |
| rs11572080 | #6 |
| nicotine inhaler | #6 |
| therapy 10 weeks | #6 |
| 71 sensitivity | #6 |
| breakthrough nausea | #6 |
| flashes humans | #6 |
| fatigue pilot study | #6 |
| alliance clinical | #6 |
| placebo hfs | #6 |
| proportion aes | #6 |
| life toxicity | #6 |
| loe guidelines | #6 |
| depomedroxyprogesterone acetate | #6 |
| medical acupuncture | #6 |
| severity neuropathic symptoms | #6 |
| agents breast | #6 |
| hospitalized oncology patients | #6 |
| 500 mcg | #6 |
| wisconsin ginseng | #6 |
| versus combination | #6 |
| sadenosyllmethionine treatment | #6 |
| paclitaxel peripheral neuropathy | #6 |
| staging patient outcomes | #6 |
| background chemotherapy | #6 |
| active malignancy | #6 |
| blind study | #7 |
| neuropathy oxaliplatin | #7 |
| sensitivity fecal | #7 |
| letrozole differences | #7 |
| intervention lymphedema status | #7 |
| 5fu based chemotherapy | #7 |
| patients oral cryotherapy | #7 |
| pregabalin prevention | #7 |
| citalopram cyclohexanols | #7 |
| lower extremity symptoms | #7 |
| 12 treatment arms | #7 |
| serum concentrations cytokines | #7 |
| patient anthracycline | #7 |
| follow year | #7 |
| appetites | #7 |
| prevalence moderatetosevere | #7 |
| odx score | #7 |
| transdermal clonidine | #7 |
| chronic postmastectomy pain | #7 |
| accru | #7 |
| scheduled receive | #7 |
| venlafaxine versus | #7 |
| 20 percent placebo | #7 |
| mucositis placebo | #7 |
| symptom subscale | #7 |
| cancer patients anorexia | #7 |
| induced neuropathy | #7 |
| cyclophosphamidedoxorubicin | #7 |
| venlafaxine day | #7 |
| fluoxetine clinical trials | #7 |
| patients hb response | #7 |
| vte recurrence doac | #7 |
| model estimates survival | #7 |
| minority smokers | #7 |
| smoking 3 | #7 |
| intermediate odx | #7 |
| nausea cancer patients | #7 |
| uniscale | #7 |
| incidence rbc transfusion | #7 |
| adjuvant interferon patients | #7 |
| week followup | #7 |
| study drug trial | #7 |
| venlafaxine therapy | #7 |
| paclitaxel peripheral | #7 |
| cream versus | #7 |
| fuinduced | #7 |
| throat discomfort | #7 |
| induced rash | #7 |
| rs10509681 | #7 |
| menopause hot | #7 |
| illness antimetabolites | #7 |
| 1week baseline period | #7 |
| nutrition score | #7 |
| cryotherapy arm | #7 |
| bupropion relapse | #7 |
| stage nodal status | #7 |
| study arms difference | #7 |
| pain cipn | #7 |
| weekly epoetin alfa | #7 |
| uniscale qol | #7 |
| weight concerns smokers | #7 |
| cmt genes | #7 |
| outcomes primary outcomes | #7 |
| placebocontrolled trial | #7 |
| mpa arm | #7 |
| toxic polyneuropathy | #7 |
| patients product | #7 |
| hemoquant | #7 |
| hemoccult hemoquant | #7 |
| lymphedema education | #7 |
| skindex16 | #7 |
| smokers weight concerns | #8 |
| administered systemically | #8 |
| neuropathic symptoms | #8 |
| women hfs | #8 |
| libido women | #8 |
| pros aes | #8 |
| agents newer | #8 |
| series clinical trials | #8 |
| evidence pharmacologic interventions | #8 |
| symptoms neuropathy | #8 |
| 18 months symptoms | #8 |
| greater toxicity | #8 |
| folfox dfs | #8 |
| mouth sores | #8 |
| topic antineoplastic | #8 |
| oral iron placebo | #8 |
| raw data trials | #8 |
| oral placebo | #8 |
| induced painful | #8 |
| paclitaxel pain | #8 |
| cpmp | #8 |
| antidepressant patients | #8 |
| recurrence colon cancer | #8 |
| placebo pilot study | #8 |
| direct oral factor | #8 |
| oxaliplatin paclitaxel | #8 |
| 1355 | #8 |
| odx risk | #8 |
| venlafaxine hot flashes | #8 |
| cancer survivors cipn | #8 |
| flutamide placebo | #8 |
| cycle capecitabine | #8 |
| nonhormonal treatments | #8 |
| chronic neurotoxicity | #8 |
| stomatitis patients | #8 |
| sdt1 | #8 |
| neuropathy scale | #8 |
| factors cipn | #8 |
| progestational | #8 |
| treatment cinv | #8 |
| placebo suggestion | #8 |
| anecdotal | #8 |
| efficacy newer antidepressants | #8 |
| paclitaxel severity | #8 |
| severe hot flashes | #8 |
| 70305 | #8 |
| venous toxicity | #8 |
| tamoxifeninduced hot flashes | #8 |
| opioids moderate pain | #8 |
| epa survival | #8 |
| fecal blood | #8 |
| neuropathy pain | #8 |
| oxaliplatin neuropathy | #8 |
| prior chemotherapy exposure | #8 |
| life antibodies | #8 |
| antiemetic properties | #9 |
| skindex16 scores | #9 |
| genistein tumor growth | #9 |
| cipn patients | #9 |
| follow tests | #9 |
| fatigue methylphenidate | #9 |
| acid amines | #9 |
| disease receive | #9 |
| baseline week week | #9 |
| lamotrigine pain | #9 |
| letrozole day | #9 |
| incurable disease | #9 |
| neuropathic symptoms patients | #9 |
| surgical year | #9 |
| hot flashes tamoxifen | #9 |
| flash control | #9 |
| flashes hot | #9 |
| sensory axonopathy | #9 |
| study treatment arm | #9 |
| apixaban lower rate | #9 |
| prevention vomiting | #9 |
| topical antimetabolites | #9 |
| patients hot | #9 |
| vitality subscale | #9 |
| medications evidence | #9 |
| numbness fingers | #9 |
| lymphedema prevention | #9 |
| disease recurrence recurrence | #9 |
| mometasone furoate placebo | #9 |
| fosaprepitant | #9 |
| relapse relapse prevention | #9 |
| radiationinduced esophagitis | #9 |
| appetite weight | #9 |
| dose dfmo | #9 |
| patients provided | #9 |
| 43 trials | #9 |
| trial paroxetine | #9 |
| lmwh injections | #9 |
| cancer patients cipn | #9 |
| questionnaires syndrome | #9 |
| oxaliplatin placebo | #9 |
| lymphedema hrqol | #9 |
| 5 nausea | #9 |
| ambulatory analgesics | #9 |
| cutaneous aged anesthetics | #9 |
| incidence colorectal adenomas | #9 |
| aged pilot | #9 |
| mucositis pain | #9 |
| aprepitant treatment | #10 |
| data relatedness | #10 |
| ecog kps | #10 |
| phase iii | #10 |
| physical consequences | #10 |
| incidence stomatitis | #10 |
| 40 arm | #10 |
| humans megestrol | #10 |
| δ − | #10 |
| pain medications patients | #10 |
| antineoplastic agents humans | #10 |
| folfox 5fu | #10 |
| life topic reproducibility | #10 |
| randomized placebo | #10 |
| sensitivity cancer | #10 |
| nonhormonal treatment | #10 |
| gabapentin | #10 |
| shark cartilage | #10 |
| neoplasms neuralgia | #10 |
| chemotherapy‐induced | #10 |
| trials demonstrated | #10 |
| inhibit cyp2d6 | #10 |
| life dietary supplements | #10 |
| patients treatment period | #10 |
| asco guideline | #10 |
| scrambler therapy patients | #10 |
| combination therapy relapse | #10 |
| adult cancers | #10 |
| oxaliplatin peripheral | #10 |
| factes | #10 |
| qol total | #10 |
| vaginal dryness | #10 |
| differences 5 years | #10 |
| doses citalopram | #10 |
| minocycline reduction | #10 |
| oxaliplatin trpa1 | #10 |
| flash data | #10 |
| frequency hot flashes | #10 |
| recommendations general population | #10 |
| symptomatic malignant ascites | #10 |
| ctcae grades | #10 |
| venlafaxine arm | #10 |
| anorexia cachexia | #10 |
| qol anemia | #10 |
| nonhormonal therapies | #10 |
| cancerrelated fatigue fatigue | #10 |
| cancerassociated anemia | #10 |
| megestrol acetate quality | #10 |
| patients neurotoxic chemotherapy | #10 |
| advanced cancer life | #10 |
| cognitive chemotherapy | #10 |
| controlled randomized | #10 |
| reported incidences | #11 |
| translational component | #11 |
| flashes | #11 |
| fsfi female | #11 |
| cancer undergoing | #11 |
| hydrazine sulfate | #11 |
| olanzapine chemotherapy | #11 |
| diphenhydramine lidocaine | #11 |
| antiemetic guidelines | #11 |
| dalteparin major bleeding | #11 |
| qol uniscale | #11 |
| combination treated | #11 |
| electroanalgesia | #11 |
| anastrozole 10 | #11 |
| physicians increased risk | #11 |
| difficulty patients | #11 |
| efficacy black cohosh | #11 |
| differences study arms | #11 |
| ginseng placebo | #11 |
| curve assay | #11 |
| sensory neurotoxicity | #11 |
| erythropoietic response | #11 |
| prevalence neuropathic pain | #11 |
| promising data | #11 |
| gbu | #11 |
| nicotine patch therapy | #11 |
| institutional guideline | #11 |
| ativan | #11 |
| vomiting cancer patients | #11 |
| melt curve | #11 |
| oxaliplatin induced | #12 |
| adjuvant communication decision | #12 |
| irox folfox | #12 |
| cycles drugs | #12 |
| leptin cck8 | #12 |
| recurrence comparisons | #12 |
| hb response | #12 |
| valerian placebo | #12 |
| −307 | #12 |
| ctpm | #12 |
| venlafaxine women | #12 |
| decreased libido | #12 |
| apixaban dalteparin | #12 |
| cachexia clinical trials | #12 |
| hot flashes 95 | #12 |
| completed daily | #12 |
| cipn development | #12 |
| capsaicin cream | #12 |
| rash quality | #12 |
| venlafaxine hydrochloride | #12 |
| individuals advanced adenomas | #12 |
| toxicities groups | #12 |
| patients cipn symptoms | #12 |
| gait testing | #12 |
| reported peripheral | #12 |
| toxicity 4 weeks | #12 |
| pluronic lecithin organogel | #12 |
| neurotoxic chemotherapy | #12 |
| pilot trial levetiracetam | #12 |
| breast cancer letrozole | #12 |
| probability prospective studies | #12 |
| months smoking | #13 |
| therapy benefits | #13 |
| improve cancer | #13 |
| patients advancedstage cancer | #13 |
| megestrol acetate therapy | #13 |
| autonomic scale | #13 |
| flashes day | #13 |
| initial 3 months | #13 |
| valerian sleep | #13 |
| adenomas aspirin | #13 |
| venlafaxine life | #13 |
| nausea patients | #13 |
| venlafaxine paroxetine | #13 |
| education clinical practice | #13 |
| 2000 update | #13 |
| severity hot flashes | #13 |
| oral anesthetics | #13 |
| median hb | #13 |
| life neoplasm recurrence | #13 |
| acute treatment vte | #13 |
| life investigation | #13 |
| 40 points 95 | #13 |
| paroxetine hot flashes | #13 |
| andropause | #13 |
| troubling | #13 |
| abh gel | #13 |
| weight cachexia | #13 |
| rs3213619 | #13 |
| estimates prognosis | #13 |
| hot flashes baseline | #13 |
| treatment advanced cancer | #13 |
| ncctg | #13 |
| newer antidepressants placebo | #13 |
| ais women | #13 |
| major bleeding doac | #13 |
| troublesome symptoms | #13 |
| trial support | #13 |
| neuropathic pain surgery | #13 |
| adjuvant colon cancer | #13 |
| patients diphenhydramine | #13 |
| 10 range | #13 |
| anemia life | #13 |
| neuropathy outcome | #13 |
| bmd 1 year | #13 |
| incident exposure | #13 |
| common toxicity | #13 |
| patients breakthrough cinv | #13 |
| adjuvant benefit | #13 |
| provided data | #14 |
| diagnosis localized disease | #14 |
| oxaliplatin vivo | #14 |
| recurrences patients | #14 |
| 5fu surgery | #14 |
| palliate | #14 |
| benefit toxicity | #14 |
| genital symptoms | #14 |
| based topical | #14 |
| biomarkers bone formation | #14 |
| stool dna | #14 |
| phase 3 months | #14 |
| flash activity | #14 |
| patients pain scores | #14 |
| life anemia | #14 |
| fluoxymesterone | #14 |
| smokers placebo | #14 |
| marked toxicity | #14 |
| oral iron | #14 |
| prophylactic agent | #14 |
| highly emetogenic | #15 |
| week darbepoetin | #15 |
| week baseline | #15 |
| suggestion guideline | #15 |
| life life survivors | #15 |
| monoclonal carcinoma antibodies | #15 |
| adjuvant aromatase | #15 |
| prognosis quality life | #15 |
| agents life | #15 |
| syndromes peripheral | #15 |
| bfq | #15 |
| vaginal dryness dyspareunia | #15 |
| sternal skin conductance | #15 |
| persistent incisional pain | #15 |
| grade age | #15 |
| taste alterations | #15 |
| duloxetine cipn | #15 |
| triazoles zoledronic | #15 |
| treatment weeks patients | #15 |
| androgen ablation therapy | #15 |
| academic oncologists | #15 |
| acceptability device | #15 |
| acute diarrhea patients | #15 |
| mastectomy irradiation | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| clinician perception | #15 |
| trials gabapentin | #15 |
| 16–28 | #15 |
| aes treatment | #15 |
| evidence treatment options | #15 |
| advanced malignant disease | #15 |
| lidocaine patch | #15 |
| therapy nicotine | #15 |
| advanced cancer methods | #15 |
| folfox irox | #15 |
| female cancer survivors | #16 |
| venlafaxine patients | #16 |
| premenopausal women chemotherapy | #16 |
| paclitaxel oxaliplatin | #16 |
| findings education | #16 |
| loss appetite | #16 |
| induced hot | #16 |
| stool dna test | #16 |
| dalteparin 95 | #16 |
| treatment cancer vte | #16 |
| product time | #16 |
| vte apixaban | #16 |
| measurable evaluable disease | #16 |
| endpoints baseline | #16 |
| patients venlafaxine | #16 |
| breast gynecologic cancer | #16 |
| randomized trial aspirin | #16 |
| mfsi | #16 |
| antiemetic agent | #16 |
| tingling pain | #16 |
| diarrhoea time | #16 |
| rash pruritus | #16 |
| advancedstage cancer patients | #16 |
| patch therapy | #16 |
| symptoms numbness | #16 |
| device women | #17 |
| arthralgias | #17 |
| 786 patients | #17 |
| cancer menopause | #17 |
| arhgef10 | #17 |
| vaginal symptoms | #17 |
| women metastatic | #17 |
| recommendation suggestion | #17 |
| dfs folfox | #17 |
| oxaliplatin doses | #17 |
| oxaliplatin treated | #17 |
| inadequate control | #17 |
| fractional co2 | #17 |
| study tetracycline | #17 |
| leap study | #17 |
| adenomas 1 | #17 |
| crc patients patients | #17 |
| screen detection | #17 |
| 18 months women | #17 |
| institute common | #17 |
| flashes tamoxifen | #17 |
| reduction fatigue | #17 |
| leptin concentrations groups | #17 |
| breast cancer oestrogen | #17 |
| venlafaxine | #17 |
| rs11849538 | #17 |
| treatment osteopenia | #18 |
| oncology providers patients | #18 |
| oral dronabinol | #18 |
| mri mastectomy | #18 |
| symptoms hormone | #18 |
| postmenopausal women letrozole | #18 |
| standard prognostic | #18 |
| receiving head | #18 |
| intervention guidelines | #18 |
| sternal skin | #18 |
| secondary endpoint analysis | #18 |
| flash frequencies | #18 |
| severity hot | #18 |
| menopausal problems | #18 |
| subsets age | #18 |
| patients hb | #18 |
| patients informed decisions | #18 |
| severity cipn | #18 |
| patients irox | #18 |
| prophylactic antiemetic therapy | #18 |
| sigmoidoscopy tomography | #18 |
| baseline 4 | #18 |
| data followup | #18 |
| patients overview | #18 |
| 120000 | #18 |
| randomized trials women | #18 |
| placebo 04 | #18 |
| 5 adjuvant | #18 |
| n6 n5 | #19 |
| panax quinquefolius | #19 |
| oxaliplatin carboplatin | #19 |
| 95 46 | #19 |
| flash reduction | #19 |
| unpleasant taste | #19 |
| bmd neoplasms chemotherapy | #19 |
| previous colorectal | #19 |
| minimal adverse effects | #19 |
| mastectomy methotrexate | #19 |
| physician reported | #19 |
| ncdf | #19 |
| life gabapentin | #19 |
| groups infliximab | #19 |
| treatment mastectomy | #19 |
| neoplasms peripheral | #19 |
| evidence status | #19 |
| rs7349683 | #19 |
| 7 outcomes | #19 |
| patients based chemotherapy | #19 |
| induced mucositis | #19 |
| acute cancer | #19 |
| oxaliplatin neurotoxicity | #19 |
| double blinded | #19 |
| folfox fluorouracil | #19 |
| moderate pain patients | #20 |
| emetogenic chemotherapy | #20 |
| appetite nutritional status | #20 |
| study ginseng | #20 |
| pilot trials | #20 |
| surveillance protocol | #20 |
| placebo cream | #20 |
| advanced cancer study | #20 |
| placebo smokers | #20 |
| revisitation | #20 |
| life skindex16 | #20 |
| reducing pain | #20 |
| fatigue 4 | #20 |
| progestational agents | #20 |
| numbness | #20 |
| major bleeding treatment | #20 |
| baseline week | #20 |
| palliating | #20 |
| cancer cancer therapy | #20 |
| diseases randomized | #20 |
| fecal occult | #20 |
| receiving pelvic | #20 |
| therapeutic options treatment | #20 |
| substantial problem | #21 |
| acetate patients | #21 |
| cipn symptoms | #21 |
| management cachexia | #21 |
| refractory cachexia | #21 |
| crossover analysis | #21 |
| cancer starting | #21 |
| chemotherapy agents | #21 |
| oral mucositis pain | #21 |
| radiationinduced dermatitis | #21 |
| therapy adverse effects | #21 |
| trial 12 months | #21 |
| metastatic breast carcinoma | #21 |
| treatment options women | #21 |
| female menopause | #21 |
| receptorpositive breast cancer | #21 |
| studies methylphenidate | #21 |
| routine test | #21 |
| projects quality | #22 |
| optumlabs | #22 |
| patients testosterone | #22 |
| scores ≤ | #22 |
| emetogenic | #22 |
| asco panel | #22 |
| 150 groups | #22 |
| doc time | #22 |
| location stage | #22 |
| crossover phase | #22 |
| candidate single | #22 |
| median time initiation | #22 |
| patients 5 weeks | #22 |
| subcutaneous testosterone | #22 |
| severity adverse events | #22 |
| npy leptin | #22 |
| guideline intervention | #22 |
| gain patients | #22 |
| pharmacokinetics infliximab | #22 |
| n9741 | #22 |
| acupuncture hot | #23 |
| mascc isoo | #23 |
| acetate middle | #23 |
| followup tests | #23 |
| potential toxicities | #23 |
| detecting recurrence | #23 |
| aes qol | #23 |
| fsdsr | #23 |
| mcf7 cells genistein | #23 |
| stool dna testing | #23 |
| decision adjuvant | #23 |
| life ascites | #23 |
| sucralfate patients | #23 |
| 5 pounds | #23 |
| versus delayed | #23 |
| replacement testosterone | #24 |
| randomized 1 | #24 |
| n56 | #24 |
| topic design severity | #24 |
| mirtazapine patients | #24 |
| day chemotherapy | #24 |
| design rcts | #24 |
| pilot clinical | #24 |
| weeks primary | #24 |
| hrt survival | #24 |
| aged anorexia | #24 |
| aged amines | #24 |
| ortho biotech | #24 |
| adjuvant decision making | #24 |
| female hot | #24 |
| tamoxifen octreotide | #24 |
| prevention chemotherapy | #24 |
| every3 | #24 |
| abstract5fluorouracil | #24 |
| apixaban treatment | #24 |
| qol tools | #25 |
| women adjuvant tamoxifen | #25 |
| lymphedema incidence | #25 |
| criteria adverse | #25 |
| prevention nausea | #25 |
| vte trial | #25 |
| institutional guidelines | #25 |
| bpisf | #25 |
| cancerassociated weight loss | #25 |
| antiepileptic agent | #25 |
| severe nausea vomiting | #25 |
| mmf placebo | #25 |
| placebo arm treatment | #25 |
| nausea olanzapine | #25 |
| doses schedules | #25 |
| neoplasia screening | #25 |
| trial pilot | #25 |
| cco guideline | #25 |
| recommendations basis | #25 |
| dose gabapentin | #26 |
| aiinduced | #26 |
| treatment arms | #26 |
| colorectal adenomas patients | #26 |
| undergoing adjuvant | #26 |
| cachexia carcinoma | #26 |
| irradiation mastectomy | #26 |
| oncology journals | #26 |
| joints muscles | #26 |
| trial evaluate | #26 |
| induced musculoskeletal | #26 |
| prior week | #26 |
| neoplasms estrogens | #26 |
| mfsisf | #26 |
| receiving oxaliplatin | #26 |
| 2005 update | #26 |
| agents prevention | #26 |
| regional breast | #26 |
| combination weight loss | #26 |
| syndrome menopause | #26 |
| clinical trials chemotherapy | #26 |
| nci ctc | #26 |
| series trials | #27 |
| fubased | #27 |
| neuropathy symptoms | #27 |
| patients short term | #27 |
| prophylactic antiemetic | #27 |
| antiemetic | #27 |
| lmwh survival | #27 |
| events ctcae | #27 |
| smoking bupropion | #27 |
| lymphedema arm | #27 |
| hot flashes hf | #27 |
| adjuvant 5fu | #27 |
| valerian | #27 |
| nurse survey | #27 |
| recommendations trials | #27 |
| fluoxetine citalopram | #28 |
| matched general population | #28 |
| chest rays | #28 |
| mastectomy rate | #28 |
| standard prognostic factors | #28 |
| lidocaine patches | #28 |
| intractable palliative | #28 |
| definitively | #28 |
| prevent colorectal adenomas | #28 |
| muscles joints | #28 |
| gynecologic cancer survivors | #28 |
| treatment hot flushes | #28 |
| alliance | #28 |
| describers | #28 |
| primary endpoint proportion | #28 |
| newer | #28 |
| survival arms | #29 |
| smokers bupropion | #29 |
| statistical controversies | #29 |
| asco guideline update | #29 |
| efficacy venlafaxine | #29 |
| blood screening | #29 |
| citalopram placebo | #29 |
| placebo arm | #29 |
| points study | #29 |
| difluoromethylornithine dfmo | #29 |
| chemotherapy cipn | #29 |
| vitamin incidence | #29 |
| feet hands | #29 |
| pain cancer survivors | #29 |
| taxanebased chemotherapy | #29 |
| mucositis study | #29 |
| patients paclitaxel | #29 |
| paclitaxel cipn | #29 |
| biological predictors | #29 |
| small pilot | #30 |
| usual oncology | #30 |
| postmenopause predictive | #30 |
| benadryl | #30 |
| development cipn | #30 |
| twoyear followup | #30 |
| mild nausea | #30 |
| contralateral axillary | #30 |
| diseases peripheral | #30 |
| phase iii comparison | #30 |
| cipn pain | #30 |
| pain oral | #30 |
| management oral mucositis | #30 |
| middle aged postmenopause | #30 |
| alfa darbepoetin | #30 |
| month duration | #30 |
| loss postmenopausal | #30 |
| anthrapyrazoles | #30 |
| term rectal | #31 |
| patients races | #31 |
| treatment paclitaxel | #31 |
| ixabepilone patients | #31 |
| prevention oral mucositis | #31 |
| calcium magnesium | #31 |
| sixtysix patients | #31 |
| pain quality life | #31 |
| management menopausal symptoms | #31 |
| middle aged perimenopause | #31 |
| treatment acute vte | #31 |
| benefit dfs | #31 |
| patients secondary analysis | #31 |
| symptomatic ascites | #31 |
| efficacy methylphenidate | #31 |
| arms placebo | #31 |
| mastectomy mri | #31 |
| female services | #32 |
| doubleblind trial | #32 |
| camg | #32 |
| vera gel | #32 |
| rash severity | #32 |
| delayed chemotherapy | #32 |
| evidencebased guidance | #32 |
| receiving highly | #32 |
| oncologist patients | #32 |
| women lymphedema | #32 |
| breast cancer symptoms | #32 |
| guideline endorsement | #32 |
| pursuant | #33 |
| neuropathy patients | #33 |
| fingers hands | #33 |
| chemotherapeutic regimens | #33 |
| dose megestrol | #33 |
| therapy bupropion | #33 |
| breast neoplasms life | #33 |
| smokers randomized | #33 |
| increased difficulty | #33 |
| 4week followup | #33 |
| instruments life | #33 |
| aloe vera gel | #33 |
| blind manner | #33 |
| patients taxol | #33 |
| toxicity breast | #33 |
| questionnaires total | #33 |
| week treatment | #33 |
| painful cipn | #33 |
| patients cinv | #33 |
| acupuncture hot flashes | #33 |
| isoo | #33 |
| sensitivity polyps | #33 |
| survival advanced cancer | #33 |
| neoplasms carboplatin | #33 |
| hands feet | #33 |
| chemotherapy hec | #34 |
| patients acitretin | #34 |
| patients nausea | #34 |
| toxicity fluorouracil | #34 |
| continuation study | #34 |
| carcinoembryonic antigen levels | #35 |
| patients tools | #35 |
| dawley statistics | #35 |
| formal consensus process | #35 |
| treating cancer | #35 |
| 4 week | #35 |
| levels week | #35 |
| moderatetosevere patients | #35 |
| trial designed | #35 |
| prevention chemotherapyinduced nausea | #35 |
| inhibitors venlafaxine | #35 |
| cipn severity | #35 |
| primary outcomes trials | #35 |
| united states hrqol | #35 |
| stomatitis | #35 |
| cancer international society | #35 |
| major bleeding lmwh | #35 |
| secondary prevention measures | #36 |
| tnfα study | #36 |
| mometasone placebo | #36 |
| myalgias | #36 |
| cohosh | #36 |
| pyrexia patients | #36 |
| pain pilot | #36 |
| head neck radiotherapy | #36 |
| lymphedema treatment | #36 |
| stages colorectal cancer | #36 |
| nk1ras | #36 |
| doxepin | #36 |
| symptoms cancer | #37 |
| p00052 | #37 |
| planned sample size | #37 |
| alleviation | #37 |
| chronic nausea | #37 |
| nausea neoplasms | #37 |
| topic stomatitis | #37 |
| cancerrelated fatigue | #37 |
| global impression | #37 |
| early integrated | #37 |
| study intravenous | #37 |
| mc5 | #37 |
| survival supportive | #37 |
| ctcae | #37 |
| topic humans life | #37 |
| patients highdose melphalan | #38 |
| fluorouracil based | #38 |
| illness purpose | #38 |
| patients taxanes | #38 |
| oncology providers | #38 |
| relationships populations | #38 |
| trial conducted | #38 |
| tests controlled trials | #38 |
| individual item | #38 |
| 5ht3ras | #38 |
| sensitization nociceptors | #38 |
| women metastatic disease | #38 |
| arm placebo | #39 |
| cohort type | #39 |
| blind crossover | #39 |
| acids drug | #39 |
| arm difference | #39 |
| trials oncology | #39 |
| european organisation cancer | #39 |
| chi2 tests | #39 |
| menopause gsm | #39 |
| qol clinical trials | #39 |
| treatment breakthrough | #39 |
| grade 2 toxicity | #39 |
| crushed ice | #39 |
| 3 agents | #39 |
| study double | #39 |
| cachexia clinical | #40 |
| mastectomy chemotherapy | #40 |
| arthralgia breast | #40 |
| single dose placebo | #40 |
| treatment analyses | #40 |
| terminology criteria | #40 |
| initial mastectomy | #40 |
| topic reproducibility surveys | #40 |
| method fatigue | #40 |
| prevent colorectal | #40 |
| patients lamotrigine | #40 |
| difluoromethylornithine | #40 |
| appetite patients | #40 |
| drug evaluation studies | #41 |
| relapse 3 months | #41 |
| zoledronic acid bmd | #41 |
| bupropion smokers | #41 |
| smokers weight | #41 |
| trial performed | #41 |
| gabapentin placebo | #41 |
| treatment period | #41 |
| undergoing androgen | #41 |
| united states guidelines | #41 |
| cure recurrence | #41 |
| symptoms 12 months | #41 |
| neuronal protection | #42 |
| patients incurable | #42 |
| appetite body | #42 |
| chemotherapy day | #42 |
| treating institution | #42 |
| placebo venlafaxine | #42 |
| nortriptyline placebo | #42 |
| randomized doubleblind trial | #42 |
| oral gabapentin | #42 |
| patients completed | #42 |
| location age | #42 |
| transdermal gel | #42 |
| sex location | #43 |
| 5 induced | #43 |
| postsurgical | #43 |
| desipramine patients | #43 |
| dietary supplements life | #43 |
| preliminary insights | #43 |
| baseline fatigue | #43 |
| highdose interferon | #43 |
| median weight | #43 |
| trial benefit | #44 |
| outcome gamma | #44 |
| pain reduction patients | #44 |
| sensory symptoms | #44 |
| collaborative effort | #44 |
| vaginal moisturizer | #44 |
| weeks efficacy | #44 |
| surveillance united states | #44 |
| bupropion placebo | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| risk cipn | #44 |
| disagreement | #44 |
| nonpain | #44 |
| conclusion trial | #45 |
| ginseng panax quinquefolius | #45 |
| humans peripheral | #45 |
| historic controls | #45 |
| piroxantrone | #45 |
| objective tumor regression | #45 |
| acute pain patients | #45 |
| genitourinary syndrome menopause | #45 |
| fisher tests | #45 |
| 5 years incidence | #45 |
| rash grade | #45 |
| menogaril | #45 |
| survivors colorectal cancer | #45 |
| vaccines melanoma | #46 |
| item measures | #46 |
| radiotherapy randomized | #46 |
| randomized comparison | #46 |
| megestrol acetate treatment | #46 |
| chemotherapy antineoplastic | #46 |
| current manuscript | #46 |
| adverse symptoms | #46 |
| cisplatin neuropathy | #46 |
| study gaba | #46 |
| patients advanced adenomas | #46 |
| clinical problem | #46 |
| middle aged patient | #46 |
| putative mechanism | #46 |
| phase iii life | #46 |
| iii colon cancer | #46 |
| longitudinal methods | #46 |
| acute skin toxicity | #46 |
| radiationinduced oral mucositis | #46 |
| nonpharmacological therapy | #46 |
| factor prognostic | #46 |
| epoetin alfa placebo | #46 |
| twopart | #47 |
| average pain | #47 |
| mascc | #47 |
| neoplasms parenteral nutrition | #47 |
| aged mometasone | #47 |
| screening setting | #47 |
| bipn | #47 |
| genetic predictors | #47 |
| darbepoetin alfa patients | #47 |
| cachexia female | #47 |
| differences pros | #47 |
| dose paclitaxel | #47 |
| physical examinations | #48 |
| qol female humans | #48 |
| nausea day | #48 |
| placebo gabapentin | #48 |
| menopause life | #48 |
| oxybutynin | #48 |
| neck radiotherapy | #48 |
| genitourinary symptoms | #48 |
| stratification factor | #48 |
| patientclinician communication | #49 |
| flie | #49 |
| sham arm | #49 |
| female cancer | #49 |
| chemotherapy nausea | #49 |
| cancer survivors fatigue | #50 |
| hot flashes hfs | #50 |
| replens | #50 |
| models stage | #50 |
| cachexia | #50 |
| mastectomy pain | #50 |
| placebos randomized | #50 |
| time conclusions | #50 |
| pain numbness | #50 |
| antiserotonergic | #50 |
| receiving androgen | #50 |
| effective treating | #51 |
| cisplatin humans | #51 |
| genitourinary syndrome | #51 |
| patients cancer pain | #51 |
| vomiting chemotherapy | #51 |
| blinded placebo | #51 |
| patients 8 weeks | #51 |
| transdermal testosterone | #51 |
| regional hypothermia | #51 |
| risk bone loss | #52 |
| aged orchiectomy | #52 |
| differences treatment arms | #52 |
| trastuzumab orr | #52 |
| metaanalysis incidence | #52 |
| management chemotherapy | #52 |
| treatment adt | #52 |
| 80k | #52 |
| black cohosh | #52 |
| cancer venous | #53 |
| toxicity time | #53 |
| nervous peripheral | #53 |
| receiving radiotherapy | #53 |
| control nausea | #53 |
| purposepatients | #53 |
| tamoxifen antineoplastic agents | #53 |
| potential adjuvant | #53 |
| antiemetics antineoplastic | #54 |
| life topic humans | #54 |
| 20 data | #54 |
| treatment months | #54 |
| standard placebo | #54 |
| double‐blind trial | #54 |
| levetiracetam treatment | #54 |
| recurrent disease | #54 |
| blood testing | #54 |
| pilot trial | #54 |
| severe hot | #54 |
| symptoms therapy | #55 |
| scalp cooling | #55 |
| acupuncture cancer | #55 |
| serial levels | #55 |
| bupropion treatment | #55 |
| cancerdirected therapy | #55 |
| cachexia therapy | #55 |
| fatigue inventory | #55 |
| treatment tobacco dependence | #55 |
| carboplatin female humans | #56 |
| symptoms hot | #56 |
| undergoing chemotherapy | #56 |
| adjuvant endocrine treatment | #56 |
| time placebo | #56 |
| xaliproden | #56 |
| diseases antineoplastic | #56 |
| benefit scale | #57 |
| 12 courses | #57 |
| placebo solution | #57 |
| recurrence symptoms | #57 |
| adjuvant colon | #57 |
| common terminology | #57 |
| topical gel | #58 |
| pain peripheral | #58 |
| compared oral | #58 |
| quality life questionnaire | #58 |
| completion adjuvant chemotherapy | #58 |
| undergoing treatment | #58 |
| skin dermatitis | #58 |
| major bleeding enoxaparin | #58 |
| points placebo | #58 |
| ferric gluconate | #58 |
| cachexia weight loss | #58 |
| limited degree | #58 |
| weight appetite | #59 |
| placebo citalopram | #59 |
| data understanding | #59 |
| safety rivaroxaban | #59 |
| ocular irritation | #59 |
| coprescription | #59 |
| chemotherapy cognitive | #59 |
| osteopaenia | #59 |
| patients hec | #59 |
| chemotherapyinduced nausea | #59 |
| colonoscopically | #60 |
| serotonergic effects | #60 |
| study medication | #60 |
| anticonvulsants antidepressive | #60 |
| hb baseline | #60 |
| patients mirtazapine | #60 |
| sensitivity individuals | #61 |
| lymphedema women | #61 |
| bleomycin patients | #61 |
| emla cream | #61 |
| caregivers pain | #61 |
| tamoxifen metabolism | #61 |
| standard dosing | #61 |
| 3 randomized | #61 |
| pipn | #61 |
| 1 week treatment | #61 |
| doubleblind | #61 |
| cancer patients study | #61 |
| paroxetine fluoxetine | #61 |
| topic surveys life | #61 |
| pain bleeding | #62 |
| chemotherapy dose | #62 |
| venlafaxine placebo | #62 |
| dermatological toxicities | #62 |
| induced taste | #62 |
| fluorouracil induced | #62 |
| ocular toxicity | #62 |
| recurrent disease patients | #62 |
| efficacy fluoxetine | #62 |
| alpha weight | #62 |
| 105 months | #63 |
| ncictc | #63 |
| antibodies monoclonal carcinoma | #63 |
| lessen | #63 |
| aged placebos | #63 |
| anorexia patients | #63 |
| integrative oncology | #63 |
| patients disease recurrence | #63 |
| prior chemotherapy regimen | #63 |
| allelic variability | #64 |
| versus placebo | #64 |
| treatment chemotherapy | #64 |
| alleviate | #64 |
| aged nausea | #64 |
| improvement sexual function | #64 |
| cyclohexanols | #64 |
| cyproheptadine | #64 |
| patients cancer types | #64 |
| carboplatin oxaliplatin | #64 |
| rivaroxaban enoxaparin | #64 |
| painful peripheral neuropathy | #64 |
| bupropion nicotine | #64 |
| incidence rash | #64 |
| 75 daily | #65 |
| agents double | #65 |
| survivorship issues | #65 |
| 4 weeks week | #65 |
| dalteparin treatment | #65 |
| validated patient | #65 |
| administration paclitaxel | #65 |
| efficacy toxicity | #65 |
| patients minocycline | #65 |
| patients comparisons | #65 |
| appetite weight loss | #65 |
| food intake patients | #66 |
| placebo months | #66 |
| oncology clinical | #66 |
| acetate therapy | #66 |
| nicotine nasal | #66 |
| study gabapentin | #66 |
| diseases neoplasms | #66 |
| clinician training | #67 |
| target doses | #67 |
| life topic | #67 |
| qol fatigue | #67 |
| estrogen suppression | #67 |
| prevention smoking | #68 |
| 46 95 | #68 |
| pilocarpine treatment | #68 |
| cachexia weight | #68 |
| baseline study | #68 |
| induced dermatitis | #68 |
| hormonal therapies | #68 |
| patients randomized | #68 |
| hec | #68 |
| subcutaneous dalteparin | #68 |
| skin surveys | #69 |
| gained weight | #69 |
| debilitating | #69 |
| ongoing loss | #69 |
| vasomotor symptoms women | #69 |
| fsfi score | #69 |
| item score | #70 |
| women ais | #70 |
| development severity | #70 |
| chemotherapy anemia | #70 |
| induced ovarian | #70 |
| surgery cancer | #70 |
| multifactorial syndrome | #70 |
| nonsignificant trends | #70 |
| week percentage | #71 |
| anthrapyrazole | #71 |
| life referral | #71 |
| incidence severity | #71 |
| major bleeding apixaban | #71 |
| infliximab combination | #71 |
| weight compared | #71 |
| placebo patches | #72 |
| patients pilot | #72 |
| trials planning | #72 |
| effects ginseng | #72 |
| oral drug administration | #72 |
| humans lignans | #72 |
| cisplatin treated | #72 |
| systemic retinoids | #72 |
| ergotamines | #73 |
| chemoprevention trial | #73 |
| chemotherapy supportive | #73 |
| weeks placebo | #73 |
| ginseng treatment | #73 |
| placebo | #73 |
| stage primary | #73 |
| prospective pilot trial | #73 |
| rcts systematic reviews | #74 |
| anemia antineoplastic | #74 |
| dronabinol | #74 |
| women estrogen therapy | #74 |
| receiving chemotherapy | #74 |
| fractional co2 laser | #74 |
| rash | #74 |
| trial evaluating | #74 |
| qli | #74 |
| prevention | #75 |
| nervous diseases | #75 |
| acid supplement | #75 |
| cancerrelated fatigue crf | #75 |
| 353 patients | #75 |
| weekly arm | #76 |
| inhibitors tamoxifen | #76 |
| acute skin | #76 |
| blind clinical | #76 |
| cycles cycle | #76 |
| 95 01 | #77 |
| anorexia weight loss | #77 |
| anemia darbepoetin | #77 |
| week p005 | #77 |
| alliance patients | #77 |
| breast cancer paclitaxel | #77 |
| cancer randomized | #77 |
| dose 90 | #77 |
| hospice staff | #77 |
| tamoxifen postmenopausal | #77 |
| 3 arm | #78 |
| patients zoledronic acid | #78 |
| values data | #78 |
| tamoxifen postmenopausal women | #78 |
| female humans insurance | #78 |
| patients darbepoetin alfa | #79 |
| therapy antineoplastic | #79 |
| symptoms sensitivity | #79 |
| vte recurrence | #79 |
| surgery year | #79 |
| pain syndrome | #79 |
| week schedule | #79 |
| serum concentrations infliximab | #79 |
| efficacy lamotrigine | #79 |
| isoflavone supplements | #80 |
| zoledronic acid treatment | #80 |
| time mastectomy | #80 |
| foot syndrome | #80 |
| life phase iii | #80 |
| vomiting antiemetics | #80 |
| week 4 | #80 |
| lowmolecular weight heparin | #81 |
| patient qol | #81 |
| patients treatment arms | #81 |
| guideline recommendation | #81 |
| period crossover | #81 |
| study march | #81 |
| oral oncology | #81 |
| backgroundchemotherapy | #82 |
| bupropion smoking | #82 |
| paroxetine patients | #82 |
| greater weight gain | #82 |
| suggestion | #82 |
| standard clinical | #82 |
| patients participating | #83 |
| recommendations article | #83 |
| orbital stability | #83 |
| day weeks | #83 |
| trpv1 trpa1 | #83 |
| zinc sulfate | #84 |
| trpm8 trpa1 | #84 |
| method female | #84 |
| cinv patients | #84 |
| ice pack | #85 |
| neoplasm metastasis neoplasms | #85 |
| systematic reviews rcts | #85 |
| cancer weight | #85 |
| ttf survival | #86 |
| treatment nicotine dependence | #86 |
| mayo clinic | #86 |
| cryotherapy patients | #86 |
| receiving placebo | #86 |
| pilot study safety | #87 |
| incidence osteoporosis | #87 |
| life cachexia | #87 |
| primary symptom | #87 |
| methodspatients | #87 |
| therapyinduced | #87 |
| nicotine nasal spray | #87 |
| week 5 | #87 |
| serum hepcidin levels | #87 |
| baseline arms | #87 |
| frequency severity | #87 |
| acp documentation | #88 |
| integrative therapies | #88 |
| anecdotal reports | #88 |
| putative mediator | #89 |
| cancer vte | #89 |
| treatment fatigue | #89 |
| iu daily | #89 |
| clinical oncology asco | #90 |
| male chemotherapy | #90 |
| morphine pharmacokinetics | #90 |
| outcome venlafaxine | #90 |
| ncorp | #91 |
| tolerated patients | #91 |
| endoxifen concentrations | #91 |
| symptoms including | #91 |
| arm treatment | #91 |
| scores placebo | #91 |
| iii efficacy | #91 |
| delayed cinv | #91 |
| patients upfront | #92 |
| cisplatin oxaliplatin | #92 |
| completion chemotherapy | #92 |
| trials treatment | #92 |
| nerve pain | #92 |
| patients paroxetine | #92 |
| ameliorating | #93 |
| anemic patients | #94 |
| duloxetine hydrochloride | #94 |
| neoplasms quality life | #94 |
| quiet stance | #94 |
| apixaban dose | #94 |
| arm 3 | #94 |
| questionnaires survival | #94 |
| mometasone | #94 |
| breast cancer survivors | #94 |
| 1 primary | #94 |
| alfa patients | #95 |
| patients appetite | #95 |
| cancerrelated pain | #95 |
| common symptoms | #95 |
| 0 10 | #96 |
| patients completion | #96 |
| udi | #96 |
| hlaa2 patients | #96 |
| ccop | #96 |
| failure chemotherapy | #96 |
| mayo clinic rochester | #96 |
| prevention management | #96 |
| paclitaxel patient | #97 |
| oral mucositis patients | #97 |
| adjuvant therapy survival | #97 |
| pyrexia | #97 |
| acute vte | #97 |
| text review | #98 |
| crnmb | #98 |
| treatment tolerability | #98 |
| agents paclitaxel | #98 |
| completed study | #98 |
| alleviating | #98 |
| preliminary data | #98 |
| 15 points | #98 |
| painful area | #98 |
| identical placebo | #98 |
| bcca | #99 |
| difference incidence | #99 |
| 4 weeks baseline | #99 |
| fatigue insomnia | #99 |
| 5fu leucovorin | #99 |
| patient questionnaires | #99 |
| topic cyclophosphamide | #99 |
| induced esophagitis | #99 |
| patient medical | #99 |
| 5fluorouracil oxaliplatin | #99 |
| pregnadienediols | #99 |
| oncology outpatients | #100 |
| survival nsclc | #100 |
| 10 doses | #100 |
| clinician communication | #100 |
| male sex factors | #100 |
| qlq | #100 |
| 5 based | #101 |
| 275 patients | #101 |
| lung cancer chemoprevention | #101 |
| nortriptyline | #101 |
| antineoplastic agents life | #101 |
| oncology clinicians | #101 |
| lidocaine lidocaine | #101 |
| postresection | #101 |
| oncology asco | #101 |
| humans life | #101 |
| placebo 1 year | #102 |
| methods trial | #102 |
| variance clinical trials | #103 |
| reported effects | #103 |
| races ethnicities | #104 |
| purposeprevious | #104 |
| patients anorexia | #104 |
| quality life data | #104 |
| 3106 | #104 |
| phytogenic clinical trials | #105 |
| chemotherapy cycle | #105 |
| 12 24 months | #105 |
| patients 150 | #105 |
| diseases treatment | #105 |
| leap | #105 |
| trial studies | #106 |
| compounds oxaliplatin | #106 |
| infusion site | #106 |
| dalteparin patients | #106 |
| dfmo | #106 |
| nutritional determinants | #106 |
| months relapse | #106 |
| neuropathy | #106 |
| stool samples patients | #106 |
| pain intensity ratings | #107 |
| humans menopause | #107 |
| epoetin alfa patients | #107 |
| versus dexamethasone | #107 |
| anastrozole letrozole | #107 |
| valeriana officinalis | #107 |
| cycle cycles | #107 |
| urogenital diseases | #107 |
| women experience | #108 |
| life topic severity | #108 |
| time toxicity | #108 |
| relapse prevention | #108 |
| week study | #108 |
| breast cancer tamoxifen | #108 |
| women vasomotor symptoms | #109 |
| female urogenital | #109 |
| strong prognostic factor | #109 |
| levocarnitine | #109 |
| treatment cancer pain | #109 |
| mouthwash | #109 |
| patients guideline | #109 |
| patients cancer treatment | #110 |
| clinic rochester | #110 |
| combined paclitaxel | #110 |
| oxaliplatin therapy | #110 |
| life adverse events | #110 |
| cmf chemotherapy | #111 |
| prevention bone loss | #111 |
| egfr inhibitor | #111 |
| vomiting adult | #111 |
| function suppression | #112 |
| dosing schedules | #112 |
| insomnia pain | #112 |
| functional iron deficiency | #113 |
| colorectal neoplasia | #113 |
| agents hormonal | #113 |
| patients arms | #113 |
| visits patient | #113 |
| treatment arms patients | #113 |
| reassess | #113 |
| vestibulitis | #113 |
| –iii | #113 |
| adverse events ctcae | #113 |
| vaginal diseases | #113 |
| months 3 | #114 |
| dietary lignans | #114 |
| qol patient | #114 |
| acitretin | #114 |
| hfsd | #114 |
| therapy induced | #114 |
| cachexia humans | #114 |
| alopecia patients | #114 |
| single nucleotide variants | #114 |
| patients olanzapine | #114 |
| diseases breast | #114 |
| studies randomized | #115 |
| patients anthracycline | #115 |
| crci | #115 |
| letrozole tamoxifen | #115 |
| laser therapy lasers | #115 |
| rivaroxaban venous | #115 |
| combination nicotine | #115 |
| placebo postmenopausal women | #116 |
| treatment arm | #116 |
| oral factor | #117 |
| induction ornithine decarboxylase | #117 |
| nk1 receptor antagonist | #117 |
| patients peripheral neuropathy | #117 |
| symptoms chemotherapy | #117 |
| 2007 guidelines | #117 |
| recurrence diagnosis | #118 |
| oral antineoplastic agents | #118 |
| appetite stimulant | #118 |
| 3915 | #119 |
| preventive therapies | #119 |
| trials conducted | #119 |
| noradrenaline reuptake | #119 |
| diseases pain | #119 |
| trpa1 trpv1 | #119 |
| patients weekly paclitaxel | #119 |
| resultswhile | #120 |
| original report | #120 |
| definition classification | #120 |
| treatment weeks | #120 |
| olanzapine placebo | #120 |
| clinical histories | #120 |
| participants arms | #120 |
| 750 day | #120 |
| patients cancers | #121 |
| untoward | #121 |
| fullerton | #121 |
| postmenopausal postmenopause | #121 |
| induced ocular | #121 |
| hormonal agents | #121 |
| placebo double | #121 |
| nervous agents | #122 |
| cancer multiple | #122 |
| oxaliplatin folfox | #122 |
| acute oral | #123 |
| weeks 4 | #123 |
| rolapitant | #123 |
| netupitant | #123 |
| cancer quality | #123 |
| objective review | #123 |
| stable dose | #123 |
| surgery analysis | #123 |
| skin pain | #123 |
| treatment letrozole | #124 |
| rivaroxaban compared | #124 |
| neuropathic pain patients | #124 |
| isoflavones genistein | #124 |
| pros baseline | #124 |
| patients diploid tumors | #124 |
| survivors breast cancer | #124 |
| 90 dose | #125 |
| week dose | #125 |
| 1 month patients | #125 |
| neurotoxic agents | #126 |
| factors odds | #126 |
| resultsfour | #126 |
| recurrent adenomas | #127 |
| fsfi | #127 |
| diagnosis metastatic disease | #127 |
| genetic quality | #127 |
| hormonal breast | #127 |
| anorexia | #127 |
| patients physicians | #127 |
| promising agents | #127 |
| arms patients | #128 |
| uncommon variants | #128 |
| cancerassociated vte | #128 |
| alfa erythropoietin | #128 |
| weight concerns | #128 |
| belladonna | #128 |
| postural instability | #129 |
| vomiting cinv | #129 |
| agents neoplasms | #129 |
| neoplasms quality | #129 |
| 5 leucovorin | #129 |
| clinical trial patients | #129 |
| resultsforty | #129 |
| patientreported outcome | #130 |
| problem patients | #130 |
| serum baseline | #130 |
| control arms | #130 |
| cancer fatigue | #131 |
| treatment toxicities | #131 |
| bmd tscore | #131 |
| prognostic variables | #131 |
| 150 iu | #131 |
| function fsfi | #131 |
| pilot data | #132 |
| onycholysis | #132 |
| neurotoxicity syndromes | #132 |
| cancerrelated symptoms | #132 |
| relapse smoking | #132 |
| efficacy vitamin | #132 |
| assessable | #133 |
| progress report | #133 |
| cachexia patients | #133 |
| topical treatment | #133 |
| symptom control | #134 |
| endodermal sinus tumor | #134 |
| ginseng panax | #134 |
| ganglion block | #134 |
| 5 placebo | #134 |
| bmd postmenopausal women | #135 |
| 150 women | #135 |
| cold hyperalgesia | #135 |
| chemotherapy 5 | #135 |
| common adverse effects | #135 |
| cancers patients | #135 |
| agents generation | #135 |
| toxt | #135 |
| painful neuropathy | #136 |
| weekly therapy | #136 |
| bothersome | #136 |
| symptomatic benefit | #136 |
| patientlevel pooled analysis | #136 |
| npy levels | #136 |
| study trials | #137 |
| severe fatigue | #137 |
| percentage reduction | #137 |
| substantial benefit | #137 |
| poor qol | #137 |
| agents bortezomib | #137 |
| life physical function | #137 |
| intrapatient | #137 |
| stage cancer | #137 |
| accrued | #138 |
| hfs patients | #138 |
| grade stage | #138 |
| zoledronic | #138 |
| chemoprevention studies | #139 |
| advanced lung | #139 |
| factbr | #139 |
| incurable cancer | #139 |
| therapy breast | #139 |
| underwent mastectomy | #139 |
| patients advanced cancer | #140 |
| liquid suspension | #140 |
| breast chest wall | #140 |
| oxaliplatin chemotherapy | #141 |
| paclitaxel weekly | #141 |
| patients placebo | #141 |
| disclose | #142 |
| patients levetiracetam | #142 |
| tamoxifen placebo | #142 |
| financial concerns | #142 |
| protocols breast | #143 |
| medicine clinical | #143 |
| fluorouracil 5 | #143 |
| snv | #144 |
| preoperative magnetic | #144 |
| european organisation | #144 |
| allopurinol placebo | #144 |
| agents bone | #145 |
| eortc qlq | #145 |
| vaginal cytology | #145 |
| evidence loe | #145 |
| fluorouracil humans | #145 |
| debilitating condition | #145 |
| surgery type | #146 |
| eligible women | #146 |
| dietary counselling | #148 |
| backgroundwomen | #148 |
| oral olanzapine | #148 |
| volatile plants | #148 |
| desipramine treatment | #149 |
| numeracy | #149 |
| n201 | #150 |
| adjuvant systemic | #150 |
| venlafaxine treatment | #150 |
| predict recurrence | #150 |
| response rate survival | #151 |
| multinational association | #151 |
| women estrogen | #151 |
| daily diaries | #151 |
| intravenous access | #151 |
| patients receive | #151 |
| prior chemotherapy regimens | #151 |
| methodologic | #151 |
| caa patients | #152 |
| oral mucositis | #152 |
| 14 week | #152 |
| ovarian function suppression | #152 |
| groups symptoms | #152 |
| balance impairments | #152 |
| tumor recurrence patients | #152 |
| cramping | #153 |
| carboplatin trastuzumab | #154 |
| 80 dose | #154 |
| dermatomes | #155 |
| adjuvant systemic therapy | #155 |
| cindices | #155 |
| integrated palliative | #156 |
| combination chemotherapy cisplatin | #156 |
| vinblastine bleomycin | #156 |
| life randomized | #156 |
| mangafodipir | #156 |
| fsds | #156 |
| hyperalimentation | #156 |
| infliximab 5 | #156 |
| methods randomized | #156 |
| women breast carcinoma | #157 |
| breast cancer trastuzumab | #157 |
| racially diverse | #157 |
| gait stability | #157 |
| common terminology criteria | #157 |
| study initiation | #158 |
| oncology study | #158 |
| arm versus | #158 |
| vomiting nausea | #158 |
| induced nausea | #159 |
| physicians patients | #159 |
| iii clinical | #159 |
| weekly doses | #159 |
| chemotherapy breast cancer | #159 |
| survivors colorectal | #159 |
| european organisation treatment | #160 |
| major problem | #160 |
| cancer pain patients | #160 |
| paclitaxel taxol | #160 |
| stellate ganglion | #160 |
| treatment postmenopausal women | #160 |
| chemotherapy quality | #160 |
| women hormone therapy | #161 |
| estrogen depletion | #161 |
| validity life | #161 |
| risk infertility | #161 |
| data efficacy | #163 |
| neoplasms pain | #164 |
| efficacy women | #164 |
| current project | #165 |
| mometasone furoate | #165 |
| cisplatin vinblastine | #165 |
| pharmacokinetic analyses | #166 |
| skeletal events | #166 |
| patients 1 month | #166 |
| illness surveys questionnaires | #167 |
| osteoporosis prevention | #167 |
| life topic surveys | #167 |
| anthracycline | #168 |
| chemotherapy‐induced nausea | #168 |
| direct inhibitors | #168 |
| chemotherapy groups | #168 |
| patients data | #169 |
| dosing patients | #169 |
| 432 patients | #169 |
| menopause symptoms | #169 |
| patients adenomas | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| rochester | #171 |
| daily placebo | #171 |
| disease cmt | #171 |
| prospective clinical trials | #171 |
| global quality | #171 |
| prestudy | #172 |
| chemotherapy completion | #172 |
| placebos | #173 |
| 1 year therapy | #173 |
| judicious | #173 |
| label pilot | #173 |
| lamotrigine placebo | #173 |
| impaired balance | #173 |
| hot flushes | #173 |
| prospective evaluation | #174 |
| methylphenidate placebo | #174 |
| phase iii trial | #174 |
| diarrhoea patients | #174 |
| pilot feasibility study | #174 |
| cancer cancer treatment | #175 |
| decreased quality | #175 |
| male breast cancer | #175 |
| physician order | #175 |
| arthralgia | #175 |
| baseline weight | #176 |
| treatment 14 | #177 |
| life assessments | #177 |
| weeks women | #177 |
| bodyweights | #178 |
| thirty percent | #178 |
| life baseline | #179 |
| expected benefits | #179 |
| bothered | #179 |
| treatmentrelated toxicity | #179 |
| bolus fluorouracil | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| escalations | #182 |
| darbepoetin | #182 |
| oxaliplatin 5fluorouracil | #182 |
| ginseng | #182 |
| gain weight | #182 |
| toxicity criteria | #183 |
| peri postmenopausal women | #183 |
| organisation treatment | #183 |
| acute pain | #184 |
| white smokers | #184 |
| acetyll | #184 |
| infliximab antibodies | #184 |
| prognostic criteria | #184 |
| biostatisticians | #184 |
| received oral | #184 |
| tube primary | #184 |
| effects chemotherapy | #184 |
| outcome measures life | #185 |
| additional chemotherapy | #185 |
| reported sexual | #185 |
| arm volume | #186 |
| cinv | #187 |
| treating | #187 |
| patients drug | #187 |
| delayed nausea | #187 |
| treatment 4 weeks | #187 |
| adjuvant decision | #188 |
| reduction therapy | #188 |
| management breast cancer | #188 |
| week follow | #188 |
| lessened | #188 |
| tamoxifen letrozole | #188 |
| strong prognostic | #188 |
| troublesome | #188 |
| neoplasia female humans | #189 |
| oxaliplatin dose | #189 |
| aching | #189 |
| survivors breast | #190 |
| antiemetic regimens | #190 |
| placebo study | #190 |
| protocol therapy | #190 |
| week 1 | #190 |
| aged nitriles | #190 |
| completed baseline | #191 |
| twentyfive patients | #191 |
| cancer cancer survivors | #191 |
| manuscript | #192 |
| aches | #192 |
| fortysix patients | #192 |
| toxicity patients | #192 |
| aspirin incidence | #192 |
| patients increases | #192 |
| chronic lymphedema | #192 |
| treatment cancer patients | #192 |
| cimicifuga racemosa | #193 |
| assigned receive | #193 |
| humans isoflavones | #193 |
| weekly trastuzumab | #194 |
| 25 women | #194 |
| effective agents | #194 |
| 3 fatty | #195 |
| ornithine decarboxylase activity | #195 |
| weight loss patients | #195 |
| pain breast | #195 |
| acids double | #196 |
| resultsdata | #196 |
| trial designs | #197 |
| pituitaryadrenal axis | #197 |
| palonosetron dexamethasone | #197 |
| toxicity profiles | #198 |
| surveillance strategy | #198 |
| postmenopausal patients | #198 |
| resultstwo | #198 |
| organization treatment | #199 |
| nicotine patch | #199 |
| accent | #199 |
| delayed emesis | #199 |
| women menopause | #199 |
| culminates | #199 |
| patients letrozole | #199 |
| percent reduction | #200 |
| adjuvant interferon | #200 |
| menopause premature | #201 |
| oral glutamine | #201 |
| imiquimod | #202 |
| treatment week | #202 |
| greater 5 | #202 |
| primary goal | #202 |
| treatment bmd | #202 |
| item responses | #202 |
| cancer anemia | #203 |
| bmd postmenopausal | #203 |
| hormonal treatments | #203 |
| plo | #204 |
| composition cachexia | #204 |
| treated placebo | #204 |
| pelvic radiation therapy | #204 |
| induced oral | #205 |
| placebo 8 | #206 |
| udi6 | #206 |
| chemotherapy drugs | #206 |
| unwilling | #206 |
| leucovorin patients | #206 |
| dalteparin | #206 |
| pharmacologic interventions | #207 |
| mice cisplatin | #207 |
| heat hyperalgesia | #207 |
| 4 8 weeks | #208 |
| reduced food intake | #208 |
| incurable | #208 |
| humans leucovorin | #208 |
| chemotherapy | #209 |
| 5 daily | #209 |
| hands patients | #209 |
| estrogen receptor modulators | #210 |
| lamotrigine | #210 |
| methotrexate 5 | #210 |
| controlled evaluation | #210 |
| gel application | #211 |
| regionally advanced | #212 |
| methodsthis | #212 |
| initials | #212 |
| vomiting patients | #212 |
| diagnosis recurrence | #212 |
| docetaxel cyclophosphamide | #213 |
| trial vitamin | #213 |
| charcotmarietooth disease | #213 |
| dexamethasone control | #214 |
| oncology practices | #214 |
| patient weight | #214 |
| placebo 6 weeks | #214 |
| 15 minutes | #215 |
| olanzapine 5 | #215 |
| december patients | #215 |
| antiemetic therapy | #215 |
| oxaliplatin | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| tamoxifen users | #217 |
| gabapentin humans | #217 |
| patients duloxetine | #217 |
| women breast cancer | #217 |
| women tamoxifen | #217 |
| nonmajor | #218 |
| aprepitant | #218 |
| purposethe purpose | #218 |
| current management | #218 |
| 10 daily | #218 |
| —reply | #218 |
| placebo weeks | #218 |
| hot | #218 |
| life humans | #219 |
| nmscs | #219 |
| transdermal fentanyl | #219 |
| palliative oncology | #219 |
| sublingual administration | #220 |
| sexual symptoms | #220 |
| nonabsorbable | #220 |
| painful peripheral | #221 |
| pregabalin patients | #221 |
| society clinical oncology | #221 |
| moderate pain | #221 |
| ornithine decarboxylase odc | #221 |
| neoplasms palliative | #222 |
| prospective study women | #222 |
| ginkgo biloba egb | #222 |
| relieving | #222 |
| treatment postmenopausal | #222 |
| lymphedema patients | #222 |
| methylphenidate modafinil | #222 |
| primary breast cancer | #222 |
| furoate | #223 |
| randomized doubleblind study | #223 |
| prevention patients | #224 |
| computerized physician | #225 |
| 99 months | #225 |
| quinquefolius | #225 |
| agent patients | #226 |
| vaginal estrogen | #226 |
| partial mastectomy | #226 |
| pain presence | #227 |
| bupropion | #227 |
| turmoil | #227 |
| trial | #228 |
| clinical situation | #228 |
| 200 iu | #229 |
| nondiploid | #229 |
| secondary endpoint | #229 |
| anthracycline cardiotoxicity | #230 |
| eating disorders humans | #230 |
| akt inhibitor | #230 |
| antidepressive | #230 |
| hospice patients | #230 |
| placebo 10 | #230 |
| cancer recommendations | #230 |
| physicians quality | #230 |
| editorials | #230 |
| vitamin effects | #231 |
| rashes | #231 |
| based adjuvant | #231 |
| cachexia cytokines | #232 |
| lightheadedness | #232 |
| conclusionsthe | #232 |
| time study | #232 |
| handfoot syndrome | #232 |
| fluoxetine paroxetine | #233 |
| nonpharmacologic | #233 |
| thirty women | #234 |
| acute symptoms | #234 |
| women hot | #234 |
| 4 doses | #234 |
| treatment vte | #234 |
| arm 95 | #235 |
| relieve | #235 |
| tamoxifen neoplasms chemotherapy | #235 |
| 375 day | #235 |
| sucralfate | #235 |
| day response | #235 |
| effective treatments | #236 |
| placebo gel | #237 |
| premenopausal patients | #237 |
| antiemetics | #238 |
| postoperative monitoring | #238 |
| incidence grade | #238 |
| survivors treatment | #238 |
| letrozole patients | #238 |
| flash | #238 |
| menopause middle | #239 |
| methodswomen | #239 |
| nonpharmacologic interventions | #239 |
| adjuvant 5 | #239 |
| improved bioavailability | #239 |
| chemotherapy placebo | #239 |
| oncology clinic | #239 |
| overexpressing metastatic | #239 |
| cachexia syndrome | #240 |
| neoadjuvant therapy surgery | #240 |
| oral complications | #240 |
| treatment breast cancer | #240 |
| independent tests | #241 |
| stinging | #242 |
| participants randomized | #242 |
| small doses | #243 |
| aged paclitaxel | #243 |
| tetracycline | #244 |
| 3 arms | #245 |
| epoetin alfa | #245 |
| common practice | #246 |
| appetite stimulants | #246 |
| adjuvant oxaliplatin | #246 |
| efficacy placebo | #247 |
| mouthwashes | #248 |
| cachexia cancer | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| randomized sham | #250 |
| item scores | #250 |
| survivors adult | #250 |
| loss bmd | #250 |
| patients physical | #251 |
| major problems | #251 |
| 689 | #251 |
| topic vitamin | #252 |
| menopause women | #252 |
| coasting | #252 |
| randomised studies | #253 |
| armodafinil | #253 |
| primary point | #253 |
| moderate degree | #254 |
| nasal spray | #254 |
| average intensity | #254 |
| chemotherapy breast | #255 |
| recurrence registries | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| cancer treatment | #257 |
| antidepressant | #257 |
| therapy women | #257 |
| neoplasms randomized | #257 |
| pretreatment levels | #258 |
| women treated | #258 |
| dyspareunia | #258 |
| new therapeutic approaches | #258 |
| hydrochloride | #259 |
| rigors | #259 |
| opioid doseresponse relationship | #260 |
| tube cancer | #260 |
| inhibitors treatment | #260 |
| repeated measures | #261 |
| 1 baseline | #261 |
| patients cancer | #261 |
| common problem | #261 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| chronic post | #262 |
| dosage levels | #263 |
| months treatment | #263 |
| decision framework | #263 |
| management options | #263 |
| duloxetine placebo | #264 |
| phytogenic | #264 |
| hematinics | #264 |
| treatment oxaliplatin | #264 |
| outcome administration | #265 |
| recommendations quality | #265 |
| preoperative mri | #266 |
| treatmentrelated deaths | #266 |
| substantiation | #267 |
| placebo 8 weeks | #267 |
| treatment cancer | #267 |
| surgery adjuvant | #267 |
| paresthesia | #267 |
| individual items | #267 |
| adult cancer survivors | #268 |
| impact quality | #268 |
| 208 patients | #269 |
| patients rash | #270 |
| nausea | #270 |
| signaled | #270 |
| ginkgo biloba | #270 |
| moderate correlations | #271 |
| patients octreotide | #271 |
| 80 90 | #271 |
| estrogen antagonists | #271 |
| performance status patients | #272 |
| treatment 95 | #272 |
| score baseline | #272 |
| dna test | #272 |
| distressing | #272 |
| bridged ring | #272 |
| weekly | #272 |
| control trials | #272 |
| abstinence rates | #273 |
| placebo‐controlled trial | #273 |
| sham treatment | #274 |
| dryness | #274 |
| oncology clinical trials | #274 |
| gross disease | #275 |
| valeriana | #275 |
| induced cisplatin | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| perspiration | #278 |
| treatment breast | #278 |
| patients symptoms | #279 |
| biomarkers disease humans | #279 |
| therapeutic options | #279 |
| patients hospice | #279 |
| prominent | #279 |
| cimicifuga | #279 |
| individual patient | #280 |
| patients frequency | #280 |
| cholinergic antagonists | #280 |
| breast cancer outcomes | #280 |
| cartilage patients | #280 |
| zoledronic acid patients | #281 |
| doxorubicin cyclophosphamide | #281 |
| psychometric testing | #281 |
| chamomile | #282 |
| antidepressive agents | #282 |
| stage colon | #282 |
| greater severity | #284 |
| women effects | #284 |
| completed questionnaires | #284 |
| smoking abstinence | #285 |
| gabapentin treatment | #285 |
| early discontinuation | #286 |
| fatigue crf | #286 |
| acid adult | #287 |
| weeks patients | #287 |
| female hormone | #287 |
| paps | #287 |
| function quality | #287 |
| colorectal lung | #287 |
| symptoms function | #287 |
| hot flush | #288 |
| aromatase inhibitor therapy | #288 |
| life survival | #290 |
| eligible patients | #291 |
| clinical trial participation | #292 |
| qualitative approach | #292 |
| treatment target | #292 |
| discouraged | #292 |
| common symptom | #292 |
| mucositis oral | #293 |
| weight gain patients | #294 |
| pain symptoms | #294 |
| cbdca | #294 |
| 1636 | #294 |
| monographs | #295 |
| citalopram | #295 |
| vinca alkaloids | #295 |
| testosterone supplementation | #295 |
| bone loss patients | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| questionnaires treatment | #298 |
| aspirin placebo | #298 |
| patients entered | #298 |
| feet | #299 |
| peripheral nervous | #299 |
| neoplasms cyclophosphamide | #299 |
| inhibitors ais | #300 |
| radiation dermatitis | #300 |
| hypothetical scenarios | #300 |
| treated combination | #301 |
| shooting | #301 |
| survival trials | #302 |
| nogalamycin | #302 |
| octreotide | #302 |
| stage grade | #303 |
| treatment serum | #303 |
| acute neurotoxicity | #303 |
| symptoms pain | #304 |
| nausea vomiting | #304 |
| subscale scores | #304 |
| placebo groups | #305 |
| complementary therapies | #305 |
| schedule female | #305 |
| prime time | #305 |
| prospective clinical trial | #305 |
| factg | #306 |
| global quality life | #306 |
| aromatase inhibitor | #307 |
| placebo treatment | #307 |
| inflammatory breast cancer | #307 |
| prochlorperazine | #307 |
| shortread | #307 |
| drug embryo | #308 |
| aged cancer | #308 |
| apixaban | #308 |
| neoplasms chemotherapy | #308 |
| darbepoetin alfa | #309 |
| zoledronic acid | #310 |
| studies double | #310 |
| riskstratification | #311 |
| lung docetaxel | #311 |
| individual subject | #311 |
| advanced cancer | #311 |
| cancer receiving | #311 |
| placebo‐controlled | #312 |
| testosterone placebo | #312 |
| epoetin | #312 |
| patients cycle | #313 |
| musculoskeletal symptoms | #313 |
| syndrome aps | #314 |
| cancer adjuvant | #314 |
| or10 | #314 |
| new primary | #315 |
| operative chemotherapy | #315 |
| organoplatinum | #316 |
| article evidence | #316 |
| blinded | #317 |
| ambulatory patients | #317 |
| symptoms breast | #317 |
| bfi | #317 |
| sesame oil | #317 |
| double‐blind | #317 |
| rivaroxaban patients | #318 |
| efficacy treatment | #319 |
| irox | #319 |
| informed decisions | #321 |
| life differences | #322 |
| dietary counseling | #322 |
| thromboembolism anticoagulants | #323 |
| monthly intervals | #324 |
| smokers nicotine | #324 |
| glutamine humans | #324 |
| preventing | #325 |
| breast radiotherapy | #326 |
| nsclc chemotherapy | #326 |
| compared baseline | #327 |
| patients ductal carcinoma | #327 |
| titrate | #327 |
| continuation phase | #328 |
| vte cancer patients | #329 |
| antagonists female | #329 |
| conducted evaluate | #329 |
| lymphedema | #329 |
| patients resected | #329 |
| treatment 1 year | #329 |
| oral nutritional supplements | #329 |
| future clinical trials | #330 |
| arms | #330 |
| potential efficacy | #330 |
| controlled clinical | #330 |
| patients nasal | #330 |
| polymerase inhibitor | #331 |
| diagnosed primary | #332 |
| cancer ontario | #332 |
| lozenge | #332 |
| placebo patients | #334 |
| patients daily | #334 |
| 80 anemia | #334 |
| time disease | #335 |
| ongoing clinical | #336 |
| pain scale | #336 |
| 128 patients | #336 |
| relative benefits | #336 |
| paclitaxel therapy | #336 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| sublingual | #337 |
| survival 5 years | #338 |
| surveillance guidelines | #338 |
| discernible | #339 |
| flutamide | #340 |
| order entry | #340 |
| eligible participants | #341 |
| treatment proportion | #341 |
| mastectomy radiotherapy | #341 |
| patients 4 weeks | #341 |
| cancer cachexia | #342 |
| osteopenia osteoporosis | #342 |
| fallopian tube cancer | #342 |
| tooth disease | #343 |
| diseases quality | #343 |
| society clinical | #343 |
| pilot randomized | #344 |
| skeletal neoplasms | #345 |
| epha5 | #345 |
| clinicians patients | #345 |
| mk2206 | #346 |
| clinical problems | #346 |
| accruing | #346 |
| coumarin | #347 |
| adverse events groups | #347 |
| therapy pain | #347 |
| mucositis patients | #348 |
| sham acupuncture | #349 |
| antineoplastic therapy | #349 |
| baseline quality | #350 |
| induced acute | #350 |
| adjuvant folfox | #350 |
| vast majority | #350 |
| treatment citalopram | #351 |
| dehydroepiandrosterone dhea | #351 |
| dose schedule | #351 |
| study therapy | #352 |
| paclitaxel | #353 |
| patientreported outcomes | #353 |
| endodermal sinus | #353 |
| response letter | #353 |
| cancer life | #355 |
| risedronate | #355 |
| letrozole | #355 |
| pain baseline | #356 |
| adjuvant colonic | #359 |
| skin toxicities | #359 |
| vomiting | #359 |
| clin oncol | #360 |
| potential benefit | #360 |
| cryotherapy | #360 |
| wellknown | #360 |
| ductal situ carcinoma | #360 |
| diaries | #361 |
| began | #361 |
| direct oral | #362 |
| pelvic radiation | #362 |
| calculators | #363 |
| ovarian suppression | #363 |
| pain measures | #363 |
| nonpharmacological | #363 |
| flaxseed | #363 |
| cancer surveillance | #363 |
| completing | #365 |
| local prognosis receptor | #365 |
| ovarian fallopian | #365 |
| cddp | #365 |
| docetaxel paclitaxel | #365 |
| pain cancer | #366 |
| patients delayed | #366 |
| bioavailable testosterone | #366 |
| management cancer | #366 |
| optimal frequency | #366 |
| scalp | #367 |
| weeks study | #368 |
| 5‐year | #368 |
| scale 0 | #368 |
| aged neoplasms | #369 |
| scheduled | #369 |
| hrt risk | #370 |
| cancer received | #371 |
| skeletalrelated events | #371 |
| orally daily | #372 |
| gamma aminobutyric acid | #372 |
| 5fluorouracil 5fu | #373 |
| skin toxicity | #373 |
| symptoms patients | #373 |
| clinical oncology | #374 |
| irreversible damage | #374 |
| ecogps | #374 |
| resected stage | #374 |
| paclitaxel dose | #374 |
| ovarian failure | #374 |
| −005 | #375 |
| women breast | #376 |
| decreasing | #376 |
| therapy based | #376 |
| blood test | #377 |
| medroxyprogesterone acetate | #377 |
| humans specificity | #378 |
| drowsiness | #378 |
| week patients | #378 |
| polyneuropathy | #378 |
| assessable patients | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| fura | #381 |
| loss skeletal | #381 |
| telerehabilitation | #381 |
| 4 treatment | #382 |
| organoplatinum compounds | #383 |
| unacceptable toxicity | #383 |
| leucovorin | #383 |
| adverse event | #384 |
| target dose | #384 |
| patients capecitabine | #384 |
| 402 | #384 |
| disputes | #384 |
| function pain | #384 |
| trials involving | #384 |
| leptin patients | #385 |
| 5fluorouracil leucovorin | #385 |
| conservation agents | #385 |
| density conservation | #386 |
| fourths | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| treatment women | #390 |
| glutathione gsh | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| dying patients | #394 |
| 4 weeks | #394 |
| adjuvant trials | #394 |
| early palliative | #395 |
| discontinuation rates | #396 |
| life breast | #396 |
| performance score | #397 |
| ring compounds | #397 |
| olanzapine | #397 |
| cytotoxics | #397 |
| humans mastectomy | #397 |
| 1280 | #398 |
| paired tests | #398 |
| patients randomly | #398 |
| life data | #399 |
| fatty acid supplementation | #400 |
| chemotherapy colorectal | #400 |
| intramuscular | #400 |
| withdrew | #400 |
| peripheral neurotoxicity | #400 |
| questionnaires treatment outcome | #400 |
| 8090 | #401 |
| assigned | #401 |
| 3 cohorts | #401 |
| estrogen receptors biomarkers | #401 |
| loe | #402 |
| entered | #402 |
| evidencebased | #402 |
| female humans life | #403 |
| sadenosyllmethionine | #403 |
| acid female | #403 |
| 5 weeks | #405 |
| female fluorouracil | #406 |
| baseline demographics | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| life aged | #411 |
| patients 5fu | #411 |
| female hemorrhage humans | #412 |
| topic neoplasms | #412 |
| ornithine decarboxylase | #414 |
| regimens patients | #414 |
| placebo 2 | #415 |
| pain qol | #415 |
| based chemotherapy | #415 |
| oxaliplatin based | #415 |
| acetate | #415 |
| carboplatin patients | #416 |
| patient factors | #416 |
| oncology neoplasms | #416 |
| delayed | #417 |
| gabapentinoids | #417 |
| prospective pilot | #417 |
| platinum agents | #417 |
| receiving | #418 |
| adjuvant hormonal therapy | #419 |
| metastatic breast cancer | #419 |
| case series patients | #419 |
| nighttime sleep | #419 |
| 0 4 | #419 |
| antiemetic prophylaxis | #420 |
| study entry | #421 |
| controlled pilot | #421 |
| tcl1a | #421 |
| tamoxifen women | #421 |
| cancer purpose | #421 |
| selfreported symptoms | #422 |
| directed therapy | #422 |
| severities | #422 |
| fourth week | #422 |
| arm 2 | #423 |
| adequately | #423 |
| 5 trials | #423 |
| pyridones | #423 |
| neurophysiologic | #424 |
| anastrozole | #425 |
| androgen ablation | #425 |
| tamoxifen | #425 |
| ongoing clinical trials | #426 |
| complementary alternative | #426 |
| prevention vte | #427 |
| baseline 6 weeks | #427 |
| treating patients | #428 |
| primary peritoneal | #428 |
| gain adult | #428 |
| greater percentage | #429 |
| creatine | #429 |
| desipramine | #430 |
| adjectives | #430 |
| laser therapy | #431 |
| methodsa | #431 |
| detection colorectal | #431 |
| fatigue humans | #431 |
| hgb | #431 |
| contraindicated | #431 |
| glycitein | #431 |
| diploid tumors | #432 |
| symptom management | #432 |
| sunscreen | #433 |
| antiseizure | #433 |
| joint symptoms | #433 |
| purpose objectives | #434 |
| cancer tamoxifen | #434 |
| resultsone | #434 |
| 115 patients | #434 |
| oral calcium | #435 |
| 1157 | #436 |
| topic treatment | #436 |
| nutrition cancer | #436 |
| pains | #436 |
| olanzapine treatment | #436 |
| absolute terms | #438 |
| anthracyclinebased chemotherapy | #438 |
| clinical cancer | #438 |
| nodenegative breast cancer | #439 |
| postoperative follow | #440 |
| administration cutaneous | #440 |
| diminish | #441 |
| expected survival | #441 |
| neoplasms cancer | #441 |
| vasomotor | #442 |
| yoga | #442 |
| hgpin | #444 |
| baseline 1 month | #444 |
| preoperative breast | #445 |
| doxorubicin drug administration | #445 |
| screening colorectal | #445 |
| loss aged | #445 |
| receive | #445 |
| life efficacy | #445 |
| marie | #446 |
| agents antineoplastic | #446 |
| treatment regimen | #447 |
| acid aged | #447 |
| day dexamethasone | #447 |
| 2 months | #448 |
| patients weight | #448 |
| patients qol | #448 |
| european organization | #448 |
| estrogen therapy | #449 |
| climacteric | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| baseline 4 weeks | #452 |
| cancer symptoms | #452 |
| study feasibility | #453 |
| outline | #453 |
| nodepositive breast cancer | #454 |
| arms arm | #454 |
| postmenopause | #455 |
| dhea | #455 |
| geranium | #456 |
| 5fu patients | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| enforced | #461 |
| questionnaires terminology | #461 |
| patients venous thromboembolism | #461 |
| patients baseline | #462 |
| helpful | #462 |
| cytokines patients | #462 |
| 6 weeks | #462 |
| potential interventions | #463 |
| increased weight | #463 |
| therapy stage | #464 |
| asco | #468 |
| cancer institute | #468 |
| clin | #468 |
| referral centers | #469 |
| lung humans | #469 |
| radiation enteritis | #469 |
| consensus guideline | #470 |
| sexual distress | #470 |
| esophagitis patients | #471 |
| treatment options patients | #471 |
| purposethis | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| pilocarpine | #474 |
| 432 | #474 |
| subscale | #474 |
| hormonal replacement therapy | #475 |
| symptoms menopause | #475 |
| groups 6 months | #475 |
| uncertain | #476 |
| single item | #477 |
| appears | #477 |
| preliminary studies | #477 |
| placebo 24 weeks | #478 |
| clinical decision making | #478 |
| 95 placebo | #479 |
| doubleblind study | #479 |
| iii colon | #479 |
| onco | #479 |
| variables age | #479 |
| alopecia | #480 |
| vitamin placebo | #480 |
| enrollment patients | #480 |
| osteoporosis osteopenia | #481 |
| moderatetosevere | #482 |
| crc 95 | #482 |
| higher dose | #483 |
| adjuvant therapy | #484 |
| reluctance | #484 |
| tpn | #485 |
| locoregional disease | #485 |
| neurotoxicity patients | #485 |
| endpoints included | #485 |
| 655 | #486 |
| cure | #486 |
| blind | #488 |
| taqman pcr | #488 |
| induced neuropathic | #489 |
| estrogen deprivation | #491 |
| doselimiting toxicity | #491 |
| pain scores | #491 |
| cancer cardiovascular disease | #492 |
| plant preparations | #493 |
| combined modality treatment | #493 |
| primary breast | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| fentanyl humans | #500 |
| patients breast cancer | #500 |
| received placebo | #501 |
| “ ” | #501 |
| pilot studies | #502 |
| placebo‐controlled study | #502 |
| life questionnaires survivors | #502 |
| kps | #502 |
| metastatic cancer | #503 |
| mesonephroma | #504 |
| loss patients | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| smoking nicotine | #511 |
| placebo trial | #511 |
| preventative | #512 |
| therapy aged | #513 |
| breast diseases | #513 |
| trials data | #513 |
| flic | #514 |
| nonmetastatic breast cancer | #514 |
| advance planning acp | #514 |
| evidencebased interventions | #515 |
| premature menopause | #516 |
| women receiving | #516 |
| letrozole treatment | #516 |
| outcome antineoplastic | #517 |
| serum albumin levels | #517 |
| acute diarrhea | #519 |
| pain medications | #520 |
| achievements | #520 |
| eflornithine | #521 |
| cbcs | #521 |
| gamma aminobutyric | #522 |
| pharmaceutic | #522 |
| poorer quality life | #523 |
| mastectomy middle | #525 |
| chills | #525 |
| symptoms fatigue | #525 |
| resultsto | #527 |
| controlled crossover | #528 |
| prophylactic therapy | #528 |
| adverse events placebo | #528 |
| abt888 | #529 |
| phytogenic area | #529 |
| cmf | #529 |
| patients clinical trial | #529 |
| therapy prostate | #530 |
| oncologists | #531 |
| radiodermatitis | #531 |
| centrally | #531 |
| pregabalin | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| medications treatment | #536 |
| patients evaluated | #536 |
| antineoplastic agents | #537 |
| study week | #538 |
| agents chemotherapy | #538 |
| superficial bladder | #538 |
| weeks therapy | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| dehydroepiandrosterone | #543 |
| pain patients | #543 |
| topic severity | #543 |
| pain score | #544 |
| week 6 | #544 |
| risedronic | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| dabrafenib trametinib | #552 |
| 3 95 | #552 |
| axonal transport | #553 |
| hypesthesia | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| evaluable | #556 |
| co2 laser | #556 |
| neoplasms drug | #556 |
| regular aspirin | #556 |
| dysplastic lesions | #556 |
| abh | #557 |
| 300 day | #557 |
| vasomotor symptoms | #559 |
| reported outcomes | #560 |
| 80000 | #560 |
| emesis | #560 |
| rbc transfusions | #560 |
| moisturizer | #561 |
| methylphenidate | #561 |
| day treatment | #561 |
| mesna | #562 |
| hands | #564 |
| lmwh patients | #564 |
| time detection | #565 |
| method drug | #565 |
| induced cold | #565 |
| treatment periods | #566 |
| trial data | #566 |
| supportive cancer | #567 |
| 4 8 | #567 |
| survival stage | #567 |
| 11 months | #568 |
| scientifically | #569 |
| calgb | #569 |
| therapy primary | #569 |
| adjuvant clinical trials | #569 |
| lower dose | #571 |
| decarboxylase odc | #571 |
| topic treatment outcome | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| patients candidates | #580 |
| refute | #580 |
| methods systematic review | #580 |
| treatment phase | #581 |
| hwe | #581 |
| paced | #583 |
| breakthrough pain | #583 |
| paracentesis | #584 |
| life questionnaire | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| neoplasms nutritional | #587 |
| drug toxicity | #587 |
| paclitaxel carboplatin | #588 |
| multiple cancers | #589 |
| oxaliplatin patients | #589 |
| limited efficacy | #589 |
| aged occult | #589 |
| emotional functioning | #589 |
| muscle cramps | #589 |
| osteopenia | #590 |
| aminobutyric | #590 |
| taxane chemotherapy | #590 |
| acrin | #591 |
| ablation therapy | #592 |
| median time progression | #592 |
| crossover trial | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| pentoxifylline | #596 |
| compounded | #596 |
| sst2 | #597 |
| fatigue female | #597 |
| exanthema | #597 |
| radiotherapy breast | #597 |
| multisite | #598 |
| topic depressive disorder | #598 |
| patients mastectomy | #599 |
| publication administration | #599 |
| initial surgery | #599 |
| effects breast | #600 |
| thromboembolism vte | #600 |
| patients etanercept | #600 |
| discretion | #601 |
| 1093 | #601 |
| oral solution | #601 |
| statistically differences | #601 |
| patient decision | #601 |
| health providers | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| anthracycline based | #604 |
| cancer survivors | #604 |
| exposed patients | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| chemotherapy administration | #608 |
| toes | #608 |
| 16 women | #608 |
| iron supplementation | #609 |
| agents antidepressive | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| pilot | #613 |
| 2 95 | #613 |
| updated analysis | #614 |
| montanide | #615 |
| animal data | #616 |
| qol baseline | #616 |
| 118 patients | #617 |
| humans quality | #617 |
| commonly | #618 |
| antacid | #620 |
| appetite | #620 |
| persistent symptoms | #621 |
| urinary frequency | #621 |
| aic | #621 |
| follow median | #622 |
| itching | #625 |
| gangliosides humans | #626 |
| analyzable | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| biological targets | #634 |
| mistletoe | #634 |
| month patients | #637 |
| female sexual function | #638 |
| assessment cancer | #640 |
| dose placebo | #640 |
| serum hepcidin | #640 |
| eligible | #641 |
| poorer quality | #642 |
| inhibitors breast | #643 |
| hormonal aromatase | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| palliative quality | #647 |
| nasal symptoms | #647 |
| malignant melanomas | #648 |
| 300 patients | #648 |
| syndrome acute | #649 |
| symptoms | #649 |
| sores | #651 |
| doses patients | #651 |
| method humans | #651 |
| flushes | #651 |
| appeared | #652 |
| limiting toxicity | #653 |
| dose limiting | #653 |
| opioid analgesic | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| patients chemotherapy | #662 |
| colorectal adenocarcinoma | #662 |
| 62 months | #663 |
| 95 − | #665 |
| active agent | #666 |
| alternative treatments | #666 |
| cancer prospective | #666 |
| neoplasms patient | #666 |
| nonparametric surveys | #667 |
| life radiotherapy | #667 |
| cancer treatments | #668 |
| levetiracetam | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| marie tooth | #671 |
| paclitaxel docetaxel | #671 |
| pain adult | #674 |
| axonopathy | #674 |
| p00004 | #674 |
| 1822 | #674 |
| maintenance disorders | #675 |
| pharmacologic management | #675 |
| racially | #676 |
| induced cognitive | #676 |
| patients standard | #678 |
| 5 consecutive | #678 |
| controlled study | #679 |
| routine follow | #680 |
| diethylstilbestrol | #681 |
| reported outcome | #681 |
| purpose report | #682 |
| study samples | #684 |
| highdose melphalan | #685 |
| oncology practice | #685 |
| popularly | #685 |
| deprivation therapy | #686 |
| therapy cancer | #687 |
| fluorouracil leucovorin | #687 |
| sulindac | #688 |
| practice settings | #688 |
| neurologic injury | #688 |
| charcot marie | #688 |
| life survivors | #692 |
| pharmacological targeting | #692 |
| guideline update | #693 |
| rescue medication | #693 |
| administration schedule | #694 |
| phlebitis | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| potential benefits | #699 |
| desmethyl | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| chemopreventive agent | #704 |
| postmenopausal | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| randomized studies | #712 |
| 160 | #712 |
| erythropoiesis stimulating | #712 |
| tube neoplasms | #714 |
| newer agents | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| inflammatory breast | #717 |
| lowmolecularweight heparin | #717 |
| convened | #719 |
| endorsement | #719 |
| ameliorate | #720 |
| data baseline | #722 |
| erythropoietin female | #722 |
| cyclophosphamide methotrexate | #725 |
| humans neoplasms | #725 |
| 6 months 95 | #725 |
| palliative medicine | #725 |
| therapeutic equivalency | #727 |
| physicians predictive | #728 |
| 4 hours | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| study treatment | #731 |
| induced human | #731 |
| odc activity | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| vinca | #735 |
| medroxyprogesterone | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| chemotherapy women | #738 |
| induced neurotoxicity | #738 |
| opd | #739 |
| mirtazapine | #741 |
| locoregional therapy | #742 |
| prescribing practices | #742 |
| 4 weeks patients | #742 |
| fist | #744 |
| baseline 1 year | #745 |
| women placebo | #745 |
| armamentarium | #745 |
| patients breast | #747 |
| bone loss | #748 |
| ecog | #748 |
| trials patients | #749 |
| chemotherapy initiation | #749 |
| superficial bladder cancer | #750 |
| 271 | #750 |
| psychostimulant | #750 |
| alfa | #750 |
| cervical dysplasia | #752 |
| rand | #752 |
| compared placebo | #753 |
| complementary medicine | #753 |
| oct2 | #754 |
| antigen levels | #754 |
| radiation skin | #754 |
| 4·2 | #754 |
| 46 | #755 |
| paclitaxel chemotherapy | #755 |
| trouble | #755 |
| secondary points | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| rifngamma | #759 |
| reduction pain | #759 |
| local anesthetics | #759 |
| prostate adenocarcinoma | #760 |
| sulfasalazine | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| 81 patients | #766 |
| occult blood | #766 |
| seventy patients | #766 |
| acid 4 | #768 |
| neoplasms prospective | #768 |
| medroxyprogesterone acetate mpa | #768 |
| baseline pain | #769 |
| humans imidazoles | #769 |
| activity breast | #770 |
| actual | #770 |
| sensory neuropathy | #771 |
| breast carcinoma ductal | #772 |
| sweating | #772 |
| modified radical mastectomy | #772 |
| relatedness | #772 |
| keratinocyte growth factor | #773 |
| premenopausal women | #773 |
| primary endpoint | #773 |
| women enrolled | #773 |
| 10 day | #774 |
| emla | #774 |
| neoplasms breast | #774 |
| fifty patients | #774 |
| patients colon | #774 |
| aged peripheral | #775 |
| octreotide treatment | #776 |
| acupuncture therapy | #776 |
| oral administration | #777 |
| 257 | #777 |
| p00002 | #778 |
| gsm | #778 |
| charcot | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| benefits patients | #785 |
| skin conductance | #785 |
| cutaneous administration | #785 |
| prognostic survival | #787 |
| management | #788 |
| enoxaparin | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| subsequent cycles | #793 |
| women reported | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| clinical questions | #801 |
| life outcomes | #801 |
| neuralgia pain | #801 |
| osteoporosis women | #802 |
| erythropoiesisstimulating agents | #802 |
| day 3 | #804 |
| lack efficacy | #804 |
| randomized phase trial | #804 |
| primary points | #805 |
| glutathione | #805 |
| double | #806 |
| effects patients | #806 |
| 894 | #807 |
| opioid analgesia | #807 |
| 3 day | #808 |
| etoposide cisplatin | #808 |
| 80 antineoplastic | #808 |
| continue | #808 |
| placebotreated patients | #808 |
| 0025 | #809 |
| complete response | #811 |
| odc | #812 |
| abrogate | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| eastern cooperative | #820 |
| agents clinical | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| statisticians | #826 |
| tolerated | #826 |
| 148 patients | #827 |
| cancer control | #828 |
| rasch model | #828 |
| suggestive | #830 |
| placebo 6 months | #830 |
| cancer phase | #830 |
| administration oral | #830 |
| neoplasms bone | #832 |
| dabrafenib | #832 |
| subset analysis | #833 |
| humans medical | #833 |
| similarities differences | #835 |
| 366 | #836 |
| advanced malignancies | #836 |
| mandelic | #837 |
| prognosis quality | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| herbal products | #846 |
| adverse events aes | #846 |
| p006 | #847 |
| global qol | #848 |
| 142 patients | #848 |
| detection rates | #849 |
| toxicities | #850 |
| eortc | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| n55 | #853 |
| stage ovarian | #853 |
| oncotype | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| vaginal bleeding | #859 |
| assessment management | #859 |
| taxoids | #859 |
| stratification patients | #860 |
| published data | #860 |
| strongest | #864 |
| etidronic | #866 |
| unacceptable | #868 |
| placebo baseline | #868 |
| patients trial | #868 |
| jellies | #873 |
| efficacious | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| phytogenic carcinoma | #880 |
| nonpharmacological interventions | #880 |
| symptomatic women | #880 |
| midlife women | #881 |
| antineoplastic | #883 |
| study placebo | #883 |
| 450 | #883 |
| monoclonal antineoplastic agents | #885 |
| mitigates | #889 |
| neurotoxic | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| cancer guidelines | #894 |
| caa | #894 |
| control arm | #896 |
| completed | #900 |
| neoplasms hormone | #901 |
| oxy | #901 |
| women hormone | #902 |
| nodal status | #903 |
| inconvenience | #903 |
| percent | #903 |
| nmsc | #904 |
| provided | #905 |
| chemotherapy response | #905 |
| 00006 | #905 |
| survival surgery | #905 |
| hospices | #909 |
| chemotherapeutic | #910 |
| increased risk death | #910 |
| cancer studies | #913 |
| national cancer | #914 |
| weight maintenance | #914 |
| norepinephrine reuptake | #915 |
| paroxetine | #916 |
| life cancer patients | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| mouth mucosa | #921 |
| advanced cancer patients | #921 |
| evidence practice | #923 |
| population cohort | #924 |
| manuscripts | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| upper extremities | #929 |
| oral dosing | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| serotonin uptake | #939 |
| electronic health record | #939 |
| treatment symptoms | #940 |
| visual analogue | #940 |
| 138 patients | #942 |
| advanced adenoma | #943 |
| high‐risk | #943 |
| uptake inhibitors | #943 |
| patient population | #944 |
| letter editor | #944 |
| colorectal adenomas | #944 |
| gp100 | #945 |
| beckman | #945 |
| iii topic | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| jci | #954 |
| orally | #954 |
| participating centers | #955 |
| evaluating | #955 |
| cooperative oncology | #957 |
| adjuvant therapies | #958 |
| aloe vera | #958 |
| rheumatologic | #958 |
| hfs | #958 |
| leukopenia | #959 |
| erythropoietic | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| trpm8 | #963 |
| pjnk | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| earlystage disease | #972 |
| table | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| restarted | #977 |
| olmsted county | #977 |
| hypercalcemia | #978 |
| 1 10 | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| antidotes | #984 |
| 1 week | #984 |
| 150 | #984 |
| patients venous | #989 |
| threequarters | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| mayo | #1003 |
| bother | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| enteritis | #1028 |
| fatigue patients | #1028 |
| urogenital | #1030 |
| delayed treatment | #1031 |
| alternative treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| postural control | #1044 |
| prx | #1044 |
| randomized trial patients | #1046 |
| prevention intervention | #1047 |
| colorectal tumor | #1047 |
| patients safety | #1047 |
| substantial | #1050 |
| nutritional supplementation | #1051 |
| frey | #1051 |
| 30 40 | #1053 |
| life | #1053 |
| postchemotherapy | #1056 |
| doxorubicin female humans | #1056 |
| minority | #1057 |
| primary analysis | #1059 |
| feeding eating | #1059 |
| osteoporosis treatment | #1059 |
| 10 weeks | #1060 |
| day study | #1061 |
| tricyclic | #1061 |
| prospective validation | #1063 |
| oncologist | #1063 |
| fruitful | #1063 |
| 347 | #1064 |
| endocrine resistance | #1064 |
| loss weight | #1066 |
| ongoing studies | #1066 |
| suggested | #1069 |
| therapy | #1069 |
| disappointing | #1069 |
| metastatic lung | #1070 |
| practical guidance | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| monoclonal humans | #1078 |
| concurrent chemotherapy | #1078 |
| nccn | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| duloxetine | #1089 |
| breast cancer recurrence | #1089 |
| prompted | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| palonosetron | #1095 |
| postoperative surveillance | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| favor | #1099 |
| intravenous iron | #1099 |
| functional ability | #1100 |
| previous chemotherapy | #1100 |
| agents treatment | #1100 |
| phytoestrogens | #1103 |
| 54 | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| interprofessional relations | #1126 |
| cancer trials | #1126 |
| dmc | #1127 |
| unpleasant | #1127 |
| prilocaine | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| clinician | #1133 |
| patients versus | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| opioid therapy | #1139 |
| 25 micrograms | #1139 |
| hormonal therapy | #1140 |
| practice guideline | #1140 |
| cancer | #1141 |
| inhibit | #1144 |
| purposeto | #1144 |
| egb | #1146 |
| randomized crossover | #1146 |
| cancer pain | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| premature ovarian failure | #1150 |
| shark | #1150 |
| purpose determine | #1150 |
| 730 | #1153 |
| nervousness | #1153 |
| smoking prevention | #1154 |
| hormonal | #1154 |
| detrimental | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| rinse | #1162 |
| 22 | #1162 |
| doac | #1163 |
| educate | #1164 |
| toxicity assessment | #1167 |
| purposethis study | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| painful | #1174 |
| therapy estrogens | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| prior treatment | #1189 |
| international consensus | #1189 |
| mastectomy breast | #1190 |
| acetate treatment | #1190 |
| usage | #1193 |
| gained | #1196 |
| estrogen replacement therapy | #1197 |
| diary | #1197 |
| olmsted | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| 552 | #1204 |
| partial responses | #1204 |
| male smokers | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| satisfied | #1212 |
| breast cancer | #1212 |
| induced skin | #1213 |
| communication skills | #1215 |
| patients pts | #1215 |
| 611 | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| sexuality | #1219 |
| precludes | #1219 |
| secondary endpoints | #1219 |
| 8 week | #1221 |
| phase clinical trial | #1223 |
| higher numbers | #1223 |
| limiting | #1224 |
| editor | #1227 |
| thighs | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| primary melanomas | #1232 |
| 8 weeks | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| discontinue | #1235 |
| randomized phase | #1235 |
| tricyclic antidepressants | #1241 |
| clinical syndrome | #1241 |
| baseline values | #1245 |
| review data | #1248 |
| day 2 | #1248 |
| symptoms diagnosis | #1248 |
| decided | #1249 |
| etiologies | #1250 |
| female sexual | #1250 |
| postmenopausal women | #1252 |
| bedtime | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| combination docetaxel | #1258 |
| diphosphonates | #1258 |
| thromboembolism patients | #1258 |
| hypochromic | #1259 |
| patients 4 | #1259 |
| trametinib | #1259 |
| rasch | #1260 |
| kidney dysfunction | #1260 |
| pain medication | #1261 |
| neurologic humans | #1263 |
| doubts | #1263 |
| dna ploidy | #1265 |
| tumor promotion | #1265 |
| esophagitis | #1266 |
| sae | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| drug double | #1272 |
| qol scores | #1272 |
| situ carcinoma ductal | #1273 |
| short form36 | #1273 |
| patients families | #1274 |
| preoperative chemotherapy | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| taxanes | #1279 |
| tamoxifen patients | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| cyclophosphamide doxorubicin | #1289 |
| adjuvant therapy patients | #1289 |
| opposed | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| cochran | #1294 |
| acupuncture treatment | #1294 |
| data clinical | #1296 |
| prevalence severity | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| abstinent | #1307 |
| 8 cycles | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| melanoma antigen | #1315 |
| biotech | #1315 |
| gsh | #1315 |
| breast biopsy | #1317 |
| contacted | #1318 |
| durations | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| oncology patients | #1321 |
| investigative | #1321 |
| controlled | #1321 |
| chemotherapeutic agents | #1321 |
| pain interference | #1322 |
| patients quality | #1322 |
| primary outcome measure | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| patient physician | #1328 |
| life scores | #1328 |
| cardiac toxicity | #1329 |
| agents colorectal | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| platinum compounds | #1347 |
| breast cancer women | #1347 |
| experienced | #1350 |
| colonoscopic | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| benefit patients | #1353 |
| cancer experience | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| patients colon cancer | #1382 |
| n29 | #1382 |
| n32 | #1382 |
| duplicates | #1386 |
| mastectomy | #1387 |
| hydrazines | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| polyneuropathies | #1407 |
| rifn | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| wilcoxon | #1416 |
| viscum | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| noncompliance | #1424 |
| subjective symptoms | #1424 |
| sleep initiation | #1424 |
| biloba | #1425 |
| methodsdata | #1426 |
| therapy initiation | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| aromatase | #1431 |
| hormonal treatment | #1431 |
| and or | #1432 |
| 5fu | #1433 |
| weight heparin | #1433 |
| statistically difference | #1434 |
| radiation injuries | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| goserelin | #1445 |
| proctitis | #1445 |
| aminobutyric acid | #1446 |
| postacute | #1447 |
| ehrs | #1447 |
| incidences | #1449 |
| cancer clinical trials | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| treatment pain | #1454 |
| nccn guidelines | #1454 |
| patients ovarian | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| individual patients | #1461 |
| effective management | #1461 |
| dna testing | #1461 |
| adjuvant treatment | #1463 |
| life cancer | #1466 |
| aged quality | #1466 |
| haloperidol humans | #1467 |
| network meta | #1467 |
| discrepancies | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| life treatment | #1477 |
| hormone dependent | #1477 |
| resultsa | #1479 |
| substantial proportion | #1479 |
| lower extremities | #1483 |
| oral aged | #1484 |
| tumor promoter | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| paclitaxel cisplatin | #1501 |
| resultsafter | #1501 |
| mpa | #1509 |
| colon cancer patients | #1510 |
| anti anxiety | #1510 |
| perimenopause | #1513 |
| gynecologic cancer | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| hair loss | #1523 |
| efficacy | #1523 |
| biweekly | #1523 |
| diagnosed cancer | #1525 |
| p0024 | #1525 |
| root ganglion | #1526 |
| oncology | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cytotoxic agents | #1537 |
| cck8 | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| male breast | #1562 |
| blind randomized | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| iii disease | #1576 |
| pharmacologic treatment | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| crushed | #1583 |
| rivaroxaban | #1583 |
| patients small | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| dissent | #1593 |
| image body | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| trpa1 | #1600 |
| stratification | #1600 |
| therapy cyclophosphamide | #1602 |
| aged cross | #1603 |
| completion | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| 2003 | #1652 |
| controlled phase | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| populationbased cohort | #1667 |
| breast cancer patients | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| anticancer therapy | #1693 |
| neoplasms practice | #1693 |
| weight patients | #1694 |
| percent patients | #1695 |
| stopping | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| nootropic | #1698 |
| patients bone | #1698 |
| randomization | #1698 |
| morpholines | #1700 |
| patients control | #1701 |
| symptom distress | #1701 |
| endpoint | #1703 |
| glutamine | #1705 |
| enrolled patients | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| chemotherapy patients | #1709 |
| 595 | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| human epidermal | #1726 |
| effects cancer | #1726 |
| referral consultation | #1728 |
| selective estrogen | #1728 |
| 652 | #1729 |
| testosterone treatment | #1729 |
| nineteen | #1730 |
| orchiectomy | #1731 |
| neuropathic pain | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| p450 cyp2d6 | #1746 |
| topical | #1746 |
| ≥10 | #1749 |
| oxcarbazepine | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| neoplasms early | #1754 |
| unique challenges | #1754 |
| treatment data | #1762 |
| greater reduction | #1762 |
| insufficient evidence | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| massage | #1766 |
| grade 2 | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| 95 0 | #1781 |
| clinical endpoints | #1781 |
| fingers | #1784 |
| objective responses | #1784 |
| behavioral interventions | #1785 |
| lignans | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| anorectic | #1791 |
| life assessment | #1791 |
| survival outcomes patients | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| alternative medicine | #1796 |
| primary therapy | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| acetylcarnitine | #1803 |
| treatment cycles | #1803 |
| severe toxicity | #1804 |
| median survival time | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| agents female | #1813 |
| 16 patients | #1813 |
| breast surgery | #1816 |
| evidencebased recommendations | #1818 |
| trpm | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| ganglion neurons | #1831 |
| humans neoplasm | #1831 |
| neoplasms prognosis | #1835 |
| longterm survival patients | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| months 12 | #1851 |
| comprehensive cancer | #1851 |
| patients prognosis | #1853 |
| 23 months | #1853 |
| neuropathic | #1853 |
| dermatological | #1853 |
| providers patients | #1857 |
| cancer types | #1858 |
| initial dose | #1858 |
| aged postmenopause | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| europe female humans | #1873 |
| humans pain | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| induced pain | #1879 |
| resultsa total | #1879 |
| musculoskeletal pain | #1881 |
| antigen colorectal | #1881 |
| analysis adult | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| schedules | #1891 |
| questionnaires time | #1891 |
| keratinocyte | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| problematic | #1899 |
| stellate | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| prematurely | #1946 |
| health personnel attitude | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| iii breast | #1971 |
| primary aim | #1971 |
| warrant | #1972 |
| articles | #1974 |
| surveillance colonoscopy | #1974 |
| initiating | #1975 |
| estrogen replacement | #1978 |
| clinical patients | #1978 |
| hand foot | #1979 |
| collaborative | #1982 |
| intravaginal | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| cancer patient | #1994 |
| androgen antagonists | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| form36 | #2018 |
| phytotherapy plant | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| perimenopausal | #2025 |
| critics | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| cancer population | #2069 |
| relaxation therapy | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| daily | #2075 |
| hb level | #2075 |
| safety pharmacokinetics | #2075 |
| 50 reduction | #2076 |
| vinblastine | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| younger women | #2087 |
| iii | #2087 |
| patients caregivers | #2088 |
| antidote | #2090 |
| advanced cancers | #2090 |
| nursing practice | #2090 |
| cco | #2094 |
| major bleeding | #2094 |
| weekly paclitaxel | #2097 |
| 66 years | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| orally administered | #2111 |
| tmt | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| bmd lumbar spine | #2121 |
| ≥2 | #2121 |
| 5fluorouracil | #2122 |
| 96 patients | #2124 |
| treatment study | #2124 |
| journals | #2125 |
| hb levels | #2126 |
| mildly | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| 525 | #2136 |
| concerned | #2136 |
| secondary objectives | #2136 |
| egfr inhibitors | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| evidence efficacy | #2166 |
| baseline | #2166 |
| treatment acute | #2169 |
| anemic | #2169 |
| aloe | #2175 |
| women | #2177 |
| album | #2179 |
| worst | #2179 |
| pain syndromes | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| 455 | #2208 |
| dose intensity | #2208 |
| female head | #2210 |
| age race | #2210 |
| prescription drugs | #2210 |
| 1 7 | #2212 |
| hypnosis | #2213 |
| ensuing | #2213 |
| weight loss | #2214 |
| recurrences | #2220 |
| 1–4 | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| osteonecrosis jaw | #2235 |
| 9 weeks | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| adrenal axis | #2247 |
| failed | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| 1 year patients | #2285 |
| oophorectomy | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| life illness | #2301 |
| therapy adt | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| polymerase inhibitors | #2310 |
| conclusionthe | #2310 |
| recommendation | #2311 |
| patch | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| 74 | #2327 |
| baclofen | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| 36 | #2333 |
| mastectomy segmental | #2333 |
| burning | #2333 |
| modest | #2334 |
| toxicity | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| opioid analgesics | #2347 |
| society | #2347 |
| androgen deprivation | #2349 |
| improve quality | #2349 |
| 46 patients | #2352 |
| curve analysis | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| density bmd | #2365 |
| cyp2d6 | #2365 |
| baseline treatment | #2367 |
| increased risks | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| counteract | #2405 |
| 266 | #2405 |
| titles | #2406 |
| inadequate | #2407 |
| treatment baseline | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| poor performance | #2419 |
| rectal cancer patients | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| advanced prostate cancer | #2425 |
| 5 patients | #2425 |
| limited evidence | #2426 |
| symptom scores | #2426 |
| debate | #2433 |
| 761 | #2436 |
| 71 patients | #2437 |
| practiced | #2437 |
| patients crc | #2439 |
| estrogen deficiency | #2439 |
| acupuncture | #2442 |
| response evaluation | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| assessment scale | #2469 |
| factor inhibitors | #2469 |
| 207 | #2474 |
| fallopian | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| 61 | #2510 |
| locoregional | #2510 |
| ginkgo | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| amitriptyline | #2542 |
| asked | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| 12 24 | #2556 |
| treatment methods | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| randomised clinical trial | #2567 |
| telopeptide | #2567 |
| nitriles | #2568 |
| treatment selection | #2570 |
| reuptake | #2570 |
| stage small | #2573 |
| earlystage breast cancer | #2573 |
| conjunctivitis | #2574 |
| trials | #2592 |
| secondary analyses | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| antineoplastic combined | #2624 |
| outcome united | #2624 |
| apr | #2626 |
| consented | #2626 |
| suspicious | #2627 |
| symptoms quality | #2629 |
| dorsal root | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| thromboembolism | #2657 |
| races | #2657 |
| 0001 patients | #2657 |
| attenuate | #2662 |
| total parenteral nutrition | #2663 |
| scores | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| modestly | #2745 |
| chemotherapy protocols | #2745 |
| thermal hyperalgesia | #2748 |
| multiple factors | #2749 |
| acp | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| male neoplasms | #2775 |
| 1 4 | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| pooled data | #2790 |
| paraneoplastic syndromes | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| ascites | #2794 |
| isoflavones | #2794 |
| agents | #2797 |
| complete data | #2799 |
| thrice | #2801 |
| nv | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| opioids | #2844 |
| meeting | #2844 |
| 38 | #2845 |
| primary outcomes | #2845 |
| cancer aged | #2854 |
| n31 | #2857 |
| cohen | #2857 |
| breakthrough | #2859 |
| linseed | #2859 |
| pharmacogenomic | #2860 |
| neoplasms | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| breaths | #2867 |
| activity level | #2867 |
| purposethe | #2869 |
| anticipate | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| 5 years patients | #2886 |
| task force | #2886 |
| ellipse | #2893 |
| survival dose | #2895 |
| p04 | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| condylomata | #2931 |
| prior | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| identifier | #2949 |
| review articles | #2949 |
| dosing regimens | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| calories | #2991 |
| started | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| objective response | #3012 |
| n5 | #3012 |
| topically | #3013 |
| time progression | #3014 |
| discomfort | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| reuptake inhibitors | #3041 |
| her2 status | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| risk colorectal | #3058 |
| relief | #3058 |
| dukes | #3058 |
| tumor activity | #3066 |
| outcome measure | #3067 |
| curve auc | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| vera | #3111 |
| bmd | #3111 |
| cancer female humans | #3111 |
| 66 | #3116 |
| neurokinin1 | #3121 |
| 26 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| supportive | #3185 |
| current approaches | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| intervention trial | #3225 |
| joint committee | #3225 |
| nonsmallcell lung cancer | #3226 |
| 39 | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| therapy combination | #3260 |
| itch | #3260 |
| intervention patients | #3263 |
| oral mucosa | #3264 |
| designed | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| 2030 | #3287 |
| root ganglia | #3287 |
| 80 antibodies | #3288 |
| 885 | #3290 |
| 695 | #3290 |
| lymphoma patients | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| treatment placebo | #3320 |
| impression | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| 171 | #3334 |
| acuminata | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| doubt | #3370 |
| bone metastases | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| 012 | #3446 |
| screening methods | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| 64 patients | #3463 |
| utilizing | #3463 |
| sprays | #3464 |
| survival benefits | #3468 |
| pts | #3468 |
| listed | #3468 |
| chemotherapy radiation | #3471 |
| anthracyclines | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| correlational | #3583 |
| phase topic | #3583 |
| survival women | #3583 |
| carboplatin paclitaxel | #3586 |
| 135 | #3586 |
| oestrogen | #3587 |
| patients experiences | #3588 |
| chemotherapy cycles | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| objective measures | #3608 |
| life qol | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| ≥30 | #3620 |
| benefits risks | #3620 |
| survival cancer | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| patients adjuvant chemotherapy | #3650 |
| colon cancer | #3650 |
| ordinal | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| sigmoidoscopy | #3682 |
| 673 | #3682 |
| preceded | #3685 |
| proportion | #3686 |
| 580 | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| anesthetics | #3811 |
| terminal | #3811 |
| hormone replacement | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| patients experienced | #3834 |
| intramuscularly | #3834 |
| 16 weeks | #3839 |
| 136 | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| blinding | #3854 |
| seventy | #3854 |
| patients grade | #3855 |
| sharks | #3855 |
| internally | #3858 |
| 23 | #3861 |
| treatment metastatic | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| publication clinical trials | #3940 |
| myoclonus | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| weight | #4002 |
| lasting | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| patients intervention | #4034 |
| audio | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| prostatic | #4062 |
| erythropoietin | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| conjunction | #4069 |
| cancer therapy | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| favoring | #4126 |
| noninfiltrating | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| tablets | #4138 |
| topic practice patterns | #4138 |
| definitions | #4138 |
| malignant melanoma | #4139 |
| femoral neck | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| depressants | #4210 |
| cancer bone | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| neoplasms colorectal | #4258 |
| contraindication | #4258 |
| serially | #4268 |
| treatment discontinuation | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| survival quality | #4284 |
| bone density | #4284 |
| day | #4285 |
| inconsistencies | #4289 |
| utilized | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| reductions | #4326 |
| prednisolone | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| primary endpoints | #4331 |
| healthy women | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| institute | #4359 |
| neoplasms combined | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| repeatedly | #4402 |
| drug combinations | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| 80 breast | #4431 |
| studies colorectal | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| improve patient | #4446 |
| day patients | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| pain measurement | #4465 |
| 80 | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| daily activities | #4523 |
| 5 | #4523 |
| sedation | #4529 |
| ganglion | #4530 |
| ductal breast | #4530 |
| gynecologic | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| stimulant | #4536 |
| disabling | #4536 |
| natural | #4537 |
| sphingolipids | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| clinical | #4564 |
| rescue therapy | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| reliability validity | #4575 |
| 4 | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| hydroxytryptamine | #4591 |
| risk bleeding | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| daily dose | #4647 |
| 6 12 | #4647 |
| neuropathies | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| dose chemotherapy | #4665 |
| adpribose | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| ” | #4734 |
| mediastinum | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| 009 | #4806 |
| corticosteroid | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| improved quality | #4818 |
| cancer compared | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| symptom burden | #4836 |
| multicenter | #4836 |
| bridged | #4837 |
| carcinoma small | #4837 |
| seer program | #4841 |
| tubulin | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| screening tool | #4956 |
| sensitization | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| genistein | #5084 |
| karnofsky performance | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| version | #5104 |
| pyrimidinones | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| physical therapy | #5131 |
| reducing | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| humans lung | #5249 |
| article | #5249 |
| insomnia | #5255 |
| patients time | #5257 |
| conventionally | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| caring | #5270 |
| low molecular | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| alkaloids | #5335 |
| anticipated | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| sensation | #5359 |
| perceived | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| officinalis | #5423 |
| stage iii | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| sensory | #5638 |
| treatment approaches | #5638 |
| new therapies | #5642 |
| lung carcinoma | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| dexamethasone | #5694 |
| renewed | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| complete | #5730 |
| specialist | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| tumor breast | #5762 |
| tumor stage | #5762 |
| interruption | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| carcinoma situ | #5783 |
| mucous | #5783 |
| nicotine | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| 405 | #5877 |
| interfere | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| insulinlike growth factor | #6013 |
| 1977 | #6013 |
| prognostic indicator | #6018 |
| descriptions | #6019 |
| minute | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| chemotherapy radiotherapy | #6041 |
| 0013 | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| disclosure | #6280 |
| psychotropic drugs | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| insignificant | #6302 |
| benzhydryl | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| aged | #6372 |
| fentanyl | #6372 |
| venous thromboembolism vte | #6385 |
| 2007 | #6385 |
| infusions | #6393 |
| epidermal growth | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| psychotropic | #6439 |
| pittsburgh | #6439 |
| entire | #6440 |
| multinational | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| intraluminal | #6471 |
| 75 | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| hemoglobins | #6612 |
| l3 | #6612 |
| decisions | #6614 |
| 287 | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| guidelines | #6646 |
| pellet | #6646 |
| crf | #6648 |
| hormone receptor | #6651 |
| patients health | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| caloric | #6694 |
| erectile dysfunction | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| radiotherapy chemotherapy | #6702 |
| hypothesized | #6702 |
| ketamine | #6710 |
| colorectal cancer patients | #6717 |
| consecutive | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| quit | #6751 |
| replacement therapy | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| search strategy | #6801 |
| longest | #6801 |
| frequently | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| controlled studies | #6810 |
| fulfilled | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| cbd | #6942 |
| factors breast | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| skin temperature | #6981 |
| regressions | #6981 |
| ais | #6986 |
| quiet | #6990 |
| calorie | #6990 |
| wearing | #6990 |
| 35 | #6994 |
| definition | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| patients 1 | #7067 |
| interested | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| prostate cancer | #7130 |
| neoplasms female | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| outpatients | #7296 |
| neoplasms primary | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| evaluates | #7353 |
| superficial | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| curative | #7416 |
| rfs | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| emphasis | #7436 |
| confirmatory | #7436 |
| receptor agonists | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| interval | #7624 |
| ploidy | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| monitored | #7699 |
| 1 day | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| surveys | #7725 |
| 021 | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| administration | #7744 |
| washout | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| impacted | #7927 |
| ago | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| comparing | #7956 |
| 5year survival | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| genders | #8063 |
| intractable | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| patients adult | #8249 |
| regard | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| pharmacogenetics | #8372 |
| year follow | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| preparations | #8422 |
| undergoing | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 37 | #8482 |
| 3 trial | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| estrogen receptors | #8637 |
| morphine | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| notable | #8700 |
| single nucleotide polymorphisms | #8700 |
| molecular markers | #8705 |
| threatening | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| mouth | #8800 |
| real | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| longer | #9020 |
| favored | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| systematic literature | #9317 |
| 94 | #9317 |
| 15 | #9332 |
| possess | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| acceptable | #9383 |
| mechanisms action | #9383 |
| drug female | #9385 |
| ambulatory | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| definitive | #9454 |
| partial response | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| 500 | #9542 |
| cancer crc | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| priority | #9791 |
| monoclonal humanized | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| avoid | #9872 |
| clinical outcomes patients | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| reactions female | #10007 |
| prescribing | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| survival dfs | #10400 |
| changed | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| mineral density | #10522 |
| longitudinal studies | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| doxorubicin | #10617 |
| counselling | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| enter | #10757 |
| anticoagulants | #10757 |
| fat mass | #10763 |
| iiia | #10779 |
| median duration | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| clinic | #10803 |
| 182 | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| international society | #11105 |
| smoking | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| practice guidelines | #11135 |
| sick | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| apparent | #11439 |
| clinical signs | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| 235 | #11509 |
| caregivers | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| definite | #11855 |
| 024 | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| referral | #11997 |
| 1998 | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| peri | #12270 |
| sodium channel | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| rank test | #12657 |
| fourteen | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| humans logistic | #13082 |
| future | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| epidemiologic | #13262 |
| humans lymphatic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| agonists | #13630 |
| improves | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| 18 years | #13813 |
| marked | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| substances | #14080 |
| lung cancer | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| protective | #14195 |
| modality | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| states aged | #14282 |
| careful | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| instance | #14341 |
| analysis performed | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| 144 | #14420 |
| produces | #14420 |
| 4 patients | #14436 |
| nodal | #14440 |
| extremity | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| episodes | #14626 |
| 09 | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| adult | #14729 |
| 008 | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| 15 years | #14762 |
| neoplasm | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| assessments | #15187 |
| colonoscopy | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 131 | #15404 |
| 197 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| updated | #15749 |
| option | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| local | #15882 |
| glandular | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| usa | #16013 |
| phenomenon | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| analysis survival | #16209 |
| 161 | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| supported | #16222 |
| neoadjuvant | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| neurotransmitter | #16320 |
| detection cancer | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| diagnostic imaging | #16418 |
| improvements | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| major | #16886 |
| rarely | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| iron deficiency | #17162 |
| diseasefree survival | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| mood | #19177 |
| inhibitor | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| authors | #22223 |
| 2005 | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| imaging mri | #23033 |
| diverse | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2017 | #23997 |
| 2011 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
रिपोर्ट चलाएं | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| के लिए जाना जाता है Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| के लिए जाना जाता है Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| के लिए जाना जाता है Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| के लिए जाना जाता है Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| के लिए जाना जाता है Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| के लिए जाना जाता है Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| के लिए जाना जाता है Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| के लिए जाना जाता है Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| के लिए जाना जाता है Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| के लिए जाना जाता है Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| के लिए जाना जाता है Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| के लिए जाना जाता है Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| के लिए जाना जाता है Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
के लिए प्रमुख लोग Hot Flashes
दुनिया में शीर्ष kols
एक खोज वाक्यांश का चयन करें hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:विशेषज्ञ प्रभाव
जिसके लिए अवधारणाएंCharles L Loprinziप्रत्यक्ष प्रभाव है:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:कोल इम्पैक्ट
अन्य लेखकों के काम से संबंधित अवधारणाएं जिनके लिएfor which Charles L Loprinzi प्रभाव है:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
क्या यह आपकी प्रोफ़ाइल है? अपनी प्रोफ़ाइल का दावा करें यूआरएल कॉपी करें अपनी प्रोफ़ाइल के लिए लिंक एम्बेड करें |